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III. Abstract 
 
Lineage-specific transcription factors determine the cell fate during development. 
Remarkably, several studies have demonstrated that ectopic overexpression of specific 
transcription factors can promote the direct conversion of one somatic cell type into another. 
Even the lineage of origin of cancer cells could be switched by this mechanism and the 
resulting cells showed impaired tumor forming potential. This approach might therefore be 
suitable as an alternative therapeutical strategy for the treatment of cancer. The aim of this 
project was to directly convert tumor cells from the keratinocytic lineage into functional and 
potentially non-tumorigenic cells from the melanocytic lineage. We hypothesize that the 
tumorigenic potential of a cancer cell is dependent on the differentiation lineage. Thus, 
transdifferentiation of squamous cell carcinoma cells (SCCs) into the melanocytic lineage 
should yield non-tumorigenic cells.  
In order to achieve this objective, different sets of candidate transcription factors were cloned 
into doxycycline-inducible lentiviral vectors and were ectopically overexpressed in a SCC 
line. 
This thesis is a proof of principle that transdifferentiation of cancer cells is possible and that 
this process can lead to loss of tumorigenic potential. After ectopic overexpression of the four 
transcription factors MITF, SOX10, SOX9 and LEF1, morphological changes towards a 
melanocyte-like appearance could be observed. Moreover, keratinocyte markers were 
downregulated and melanocyte marker expression was induced. Additionally, melanosome-
like structures were present in the transdifferentiated cells. On genomic level only minor 
changes were observed using array CGH. Also the global gene expression and the 
methylation landscape remained very similar between the parental SCC and the 
transdifferentiated cells. Yet, several characteristics including proliferation, cell metabolism, 
migration and invasion were reduced. Additionally the cells were less responsive to a cancer 
cell-specific drug combination using autophagy inhibition and an AKT inhibitor as well as to 
the treatment with the chemotherapeutic drug cisplatin. Finally, the transdifferentiated cells 
lost their tumorigenic potential, which could be shown in vivo by subcutaneous injection into 
immunosuppressed mice. To find a mechanism that could explain these observations, whole 
genome microarray and methylation array analyses were performed. After a gene set 
enrichment analysis (GSEA) IL-24 was identified as the top hit. Probably due to the 
transdifferentiation into the melanocytic lineage IL-24 became upregulated and might have 
affected the tumorigenic potential of the cells. In conclusion, we could identify a specific 
transcription factor combination which promotes the conversion of tumorigenic SCCs into 
nontumorigenic melanocyte-like cells. 
 VI 
IV. Zusammenfassung 
 
Zelltypspezifische Transkriptionsfaktoren bestimmen die Differenzierungsrichtung einer Zelle 
während der Entwicklung. Mehrere Studien haben gezeigt, dass ektopische Überexpression 
von Transkriptionsfaktoren die direkte Umwandlung von einem somatischen Zelltyp in einen 
anderen fördern kann. Sogar die Differenzierungslinie von Krebszellen kann durch diesen 
Mechanismus verändert werden. Die daraus resultierenden Zellen hatten ein gemindertes 
Potenzial einen Tumor zu bilden. Auf Grund dieser Tatsache könnte sich diese 
Herangehensweise als therapeutische Alternative für die Behandlung von 
Krebserkrankungen erweisen. Das Ziel dieser Studie war es, Krebszellen der keratinozytären 
Linie in potentiell nicht-tumorigene Zellen der melanozytären Linie umzuwandeln. Unserer 
Hypothese zu folge ist das Potential einen Tumor zu formen von der Differenzierungslinie 
abhängig. Demnach sollten durch die Transdifferenzierung von Plattenepithelkarzinomzellen 
in melanozytäre Zellen nicht-tumorformende Zellen entstehen. Um dieses Ziel zu erreichen 
wurden verschiedene Transkriptionsfaktoren in doxycycline-induzierbare lentivirale Vektoren 
kloniert und daraufhin ektopisch in Plattenepithelkarzinomzellen überexprimiert. Diese Arbeit 
zeigt, dass die Transdifferenzierung von Krebszellen möglich ist. Zudem führt diese 
Umwandlung zum Verlust des tumorigenen Potentials. Nach der ektopischen 
Überexpression der vier Transkriptionsfaktoren MITF, SOX10, SOX9 und LEF1 konnten 
morphologische Veränderungen in Richtung des melanozytären Erscheinungsbilds 
beobachtet werden. Die Expression von Keratinozytenmarkern wurde runterreguliert und 
Melanozytenmarker wurden exprimiert und melanosomartige Strukturen waren in den 
transdifferenzierten Zellen vorhanden. Nur kleine Veränderungen auf der genomischen 
Ebene wurden bemerkt. Auch die globale Genexpression sowie der Methylierungsstatus 
zeigten kaum Veränderungen zwischen den ursprünglichen und den transdifferenzierten 
Zellen. Jedoch waren mehrere Eigenschaften wie Proliferation, Zellmetabolismus, Migration 
und Invasion deutlich reduziert. Zusätzlich waren die transdifferenzierten Zellen weniger 
sensitiv gegenüber Autophagie und AKT Inhibition sowie gegenüber der Behandlung mit 
dem Chemotherapeutikum Cisplatin. Letztendlich hatten diese Zellen ihr tumorformendes 
Potential verloren was in vivo mit der subkutanen Injektion in immunsupprimierte Mäuse 
gezeigt wurde. Eine Genset Anreicherungsanalyse von Genexpressionsanalyse sowie eine 
Methylierungsanalyse um einen Mechanismus zu identifizierte resultierte in IL-24 als 
Topkandidat. Wahrscheinlich wurde die Expression von IL-24 durch die Transdifferenzierung 
in die melanozytäre Richtung aktiviert und hat auch das tumorbildende Potential der Zellen 
beeinflusst. Zusammenfassend haben wir eine spezielle Kombination von 
Transkriptionsfaktoren identifiziert, die Plattenepithelkarzinomzellen in nicht-tumorigene 
melanozyten-ähnliche Zellen umwandeln kann. 
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V. Introduction 
 
V.1. Structure and function of the skin 
The skin constitutes the main barrier, which protects the body against pathogens and other 
harmful, environmental influences as well as dehydration. Further, the skin is involved in 
thermoregulation and sensation of touch. In adults, it accounts for about 16% of the total 
body weight and is the largest organ of the body [1, 2]. Two layers execute the functions of 
the skin: the epidermis and the dermis. The epidermis is the outer layer of the skin which is 
replaced by new cells within 6-8 weeks [3] and is subdivided into four major layers: the 
stratum basale,  stratum spinosum,  the stratum granulosum and the stratum corneum. The 
basal layer of the epidermis, known as the stratum basale, consists of proliferating and non-
proliferating keratinocytes. These cells migrate outwards and differentiate on their way to 
form the other layers of the skin  [4]. Attachment to the basement membrane is given by 
hemidesmosomes [5]. Besides keratinocytes, also melanocytes and Merkel cells are present 
in this layer. Melanocytes make contacts with the surrounding keratinocytes via their 
dendritic processes. In the middle of the following layer, the stratum spinosum, Langerhans 
cells, which are immunologically active cells, can be found [6]. In the stratum granulosum 
keratinocytes lose their nuclei and show a granular cytoplasm. The stratum corneum, the 
outermost layer, serves as protection against the environment. The stratum corneum 
reaches its greatest thickness on the palms of the hands and the soles of the feet. A fifth 
layer, the stratum lucidum which is a transition between stratum granulosum and stratum 
conreum, can only be found on the palms of the hands and soles of the feet [7, 8]. The main 
function of the dermis is to offer a supporting structure to the skin. Fibroblasts in the dermis 
produce collagen and elastin, which confer stability and elasticity. The dermis is well 
vascularized to supply the skin with nutrients. Additionally the temperature of the skin is 
regulated via the blood vessels and sweat glands in the dermis. At the dermo-epidermal 
junction nerve endings are present which sense touch, temperature, pain, and pressure [2, 
9]. The hypodermis is the tissue below the dermis. Its function is to connect the skin to the 
underlying tissues. It consists mostly of fibroblasts and adipocytes, which store fat and serve 
as energy reserve, and is attached to the dermis by collagen and elastin fibers [9, 10]. 
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V.2. Cell types in the skin 
Different cell types are present in the skin serving various specific functions. Besides 
keratinocytes, melanocytes, Merkel cells, Langerhans cells, and fibroblasts build up the skin 
[1, 4]. 
Keratinocytes are the main cell type of the skin accounting for ~90% of the cells in the 
epidermis [6]. The skin layers are continuously renewed by active proliferation of 
keratinocytes. Starting at the basal layer keratinocytes travel across the epidermis to the 
stratum corneum. The cells in the stratum basale, which is a single layer of keratinocytes, 
divide and give rise to two daughter cells. One of the daughter cells remains in the basal 
layer while the other one migrates upwards and differentiates [2]. The main function of these 
cells is to produce the fibrous protein keratin, which fills their cytoplasm. On the way to the 
outer surface of the skin cells flatten and their nucleus becomes degenerated. Cohesion is 
increased by secretion of lipids, such as cholesterol, free saturated fatty acids and 
ceramides, hereby creating an efficient barrier [11]. Terminal differentiated keratinocytes in 
the outer layer, the stratum corneum, are called corneocytes. These cells have lost their 
nuclei, are completely flattened and filled with keratin which is necessary for the protective 
function of the skin [2]. A process called desquamation marks the end of the keratinocytic life 
cycle. Specific enzymes degrade cell-cell contacts leading to separation of the single 
corneocytes and ultimately loss of attachment at the surface of the skin [12].  
About 6% of the cells in the skin are Merkel cells. These tactile cells are in contact with 
sensory nerve endings to sense different stimuli such as pressure thus functioning as 
mechanoreceptors. Merkel cells can be found alone or clustered together in so called Merkel 
corpuscles [13, 14].  
 
Langerhans cells, a subset of dendritic cells were discovered by Paul Langerhans in 1868 
and first thought to be nerve cells [15]. Yet, it is known that Langerhans cells are derived 
from the bone marrow and belong to the innate immune system. Due to their antigen-
presenting ability they are also known as the ‘Guardians of the skin’ [16]. Approximately 3-
8% of the cells in the epidermis are Langerhans cells [17] .   
Melanocytes are pigment-producing cells which are derived from the neural crest. These 
cells are responsible for the pigmentation of the skin and the hair [18]. Classical melanocytes 
reside in the basal layer of the epidermis or in the hair follicle and make up about 8% of cells 
in the skin [2]. Upon ultraviolet (UV) light exposure melanocytes transfer the pigment melanin 
to the surrounding keratinocytes leading to UV protection and preventing DNA damage [9, 
19]. Melanocytes cannot only be found in the skin but are also present for example in the 
inner ear, the brain, the bones, and the heart [20]. 
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The majority of cells in the dermis are fibroblasts, which reside mostly in the dermal papillae 
in proximity to the epidermis. The main function is to produce fibers of the extracellular 
matrix. Collagen provides the dermis with resistance to stress while it is responsible for the 
elasticity of the skin [9]. 
 
V.3. Melanocyte development  
Melanocytes in the skin derive from neural crest (NC) stem cells. Several differentiation 
stages are necessary for generation of mature melanocytes. These stages can be 
distinguished by the location of the cells and distinct marker expression. The NC precursor 
cells are present in the truncal region between neural ectoderm and non-neural ectoderm. 
The fusion of the dorsal part of the neural tube leads to emergence of neural crest cells 
(NCC). These cells are now already specified and express the markers WNT1, paired box 3 
(PAX3) and forkhead box D3 (FOXD3). Thereupon, cells undergo an epithelial to 
mesenchymal transition (EMT) before migrating into the migration staging area (MSA). The 
multipotent premigratory NCCs express the NC markers SOX9 (sex determining region Y-
related HMG box 9) and SOX10 at this stage [18]. The NC gives rise to a variety of different 
cell types. During migration either along the dorsoventral or the dorsolateral pathway NCCs 
are specified. After migration along the dorsoventral pathway NCCs give rise to sensory and 
sympathetic neurons, Schwann cells, and endoneural fibroblasts among others. Dorsolateral 
migration leads to differentiation into melanocytes [19].  
Founder melanoblasts, the unpigmented precursors of melanocytes, express 
microphthalmia-associated transcription factor (MITF), PAX3 and SOX10. Predetermination 
of NCCs into melanocytes in the MSA appears already by expression of KIT and MITF 
followed by dopachrome tautomerase (DCT) [20, 21]. Due to this early specification cells 
follow the dorsolateral migration path. Yet, also external factors could influence the migration 
of cells and the specification into the melanocytic lineage. Melanoblast migration is 
accompanied by high proliferation and inhibition of apoptosis at the same time. Signaling via 
the KIT receptor pathway is crucial in this phase. These unpigmented melanocyte precursors 
migrate a far distance along a rostrocaudal gradient and colonize the whole embryo. Then 
they enter the epidermis by crossing the basal membrane. Finally, these cells migrate into 
the hair follicle expressing tyrosinase (TYR) and tyrosinase related protein1 (TYRP1), 
enzymes involved in melanogenesis, leading to pigmentation. Some cells will give rise to 
melanocyte stem cells residing in the bulge region of the hair follicle while others differentiate 
and mature to fully functional melanocytes [22]. The fully differentiated melanocytes will 
produce melanin and transfer the pigment to keratinocytes which results in pigmentation. 
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V.3.1. Genes involved in melanocyte development 
Several different molecules at various stages are necessary for differentiation of neural crest 
cells into melanocytes, as well as for proliferation and survival of the cells. 
 WNT and BMP 
WNT (wingless integrated) and BMP (bone morphogenetic protein) molecules are present 
early in the dorsal neural tube. BMP leads to differentiation into neuronal and glial cells, while 
inhibiting development of pigment cells. WNT molecules are involved in the differentiation of 
two cell types arising from the neural crest. Signaling via the WNT pathway favors outgrowth 
of sensory neurons and melanocytes. NCCs which delaminate late from the neural crest give 
rise to melanoblasts. At this stage, BMP concentrations are low while WNT signaling is still 
present. WNT molecules and beta-catenin are crucial for induction of the neural crest and 
determination of melanocytic cell fate. WNT1 and WNT3 were found to be expressed in the 
dorsal part of the neural tube. During differentiation, these factors favor the development of 
pigment cells by directly activating MITF expression via beta-catenin [23].  
 MITF 
MITF plays a central role in melanocyte development. It is a member of the basic-helix–loop–
helix-leucine-zipper (bHLH-LZ) transcription factor family, which is essential for differentiation 
into the melanocytic lineage [24]. The bHLH-LZ structure is necessary for DNA binding and 
dimer formation. MITF binds as a homo or heterodimer to the Ebox motif CANNTG [25]. The 
gene consists of nine highly conserved exons. Alternative splicing leads to at least eight 
human isoforms of MITF with varying N termini. Each of the isoforms has a separate first 
exon which is controlled by a unique promoter region [26]. MITF-M is the melanocyte specific 
isoform which can directly regulate the main enzymes involved in melanogenesis: TYR 
TYRP1 and DCT. Additional downstream targets of MITF are several melanocyte markers 
such as PMEL17, MELAN-A, MC1R, and AIM1. MITF itself is regulated by a variety of factors 
including SOX10, PAX3, beta-catenin and TCF/LEF as well as cAMP/CREB [25, 27]. 
Mutations in MITF lead amongst others to defective melanocytes and are associated with the 
auditory-pigmentation disorder Waardenburg syndrome 2 [28]. 
 PAX3 
The transcription factor PAX3 is essential for melanoblast survival and differentiation and 
thus for the expansion of the melanocyte precursor population. PAX3 belongs to the PAX 
(paired box) gene family whose members generally possess a paired box domain and a 
paired-type homeodomain. These conserved motifs are necessary for DNA binding. PAX 
transcription factors in general play important roles in embryonic development [29]. In the 
early NC, PAX3 is specifically expressed orchestrating the activity of other factors involved in 
NC differentiation [30]. Especially in the development of melanocytes PAX3 is a key player 
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during embryogenesis. It is involved in several stages such as specification, survival, 
proliferation and migration. Differentiation of cells into the melanocytic lineage is promoted by 
PAX3 due to transactivation of TYRP1. PAX3 alone can activate the MITF promoter, and 
together with SOX10 a synergistic activation can be achieved [31]. In humans, ten alternative 
splice transcripts of PAX3 exist.  Out of these ten isoforms eight encode for proteins  [32] 
which display different functions in melanocytes. PAX3 isoforms were shown to differentially 
regulate downstream targets which are involved in cell proliferation, migration, adhesion, 
apoptosis, angiogenesis and survival [29, 33]. For example the isoforms PAX3c, PAX3d and 
PAX3h were demonstrated to stimulate melanocyte proliferation. Negative regulation of cell 
proliferation in melanocytes was noted for PAX3a, PAX3b and PAX3e. No significant 
difference in cell proliferation was observed for PAX3g [33]. Transcriptional targets of PAX3 
include MITF and TYRP1 [34]. Mutations in PAX3 can lead to various diseases including 
Waardenburg syndrome, craniofacial-deafness-hand syndrome, and alveolar 
rhabdomyosarcoma [35]. 
 SOX9 and SOX10 
Two proteins of the SOX (sex determining region Y-related HMG box) family of transcription 
factors, SOX9 and SOX10, have important functions in the development of melanocytes [36, 
37]. They belong to the superfamily of high mobility group (HMG) box proteins that promote 
DNA binding through the HMG box domain in a sequence-independent, but conformation 
dependent manner. SOX9 and SOX10 belong to the SOX-E group, which additionally 
includes SOX8. SOX-E proteins promote the differentiation of NCC into various lineages [38, 
39].  
SOX9 plays a crucial role in the development of several tissues and cell types including 
various cells arising from the NC. Specifically in melanocyte development SOX9 stimulates 
the differentiation of melanocyte precursors [38]. Ectopic expression of SOX9 in NCCs favors 
the melanocytic cell fate. After differentiation of melanoblasts into mature melanocytes SOX9 
expression is increased. Additionally expression of SOX9 is found in human melanocyte 
cultures and in melanoma cell lines with a pigment phenotype [37]. Further, the function of 
SOX9 is found to be controlled by signaling via the cAMP pathway. It is known that cAMP is 
important for the development and differentiation of melanocytes [40]. SOX9 might be 
activated by molecules which can increase cAMP concentration and in this way is involved in 
the induction of melanocyte cell fate and maturation. 
SOX10 is suggested to influence the NC in different ways, such as facilitation of NC stem cell 
maintenance, but also specification and differentiation of distinct cell types [41, 42]. The 
expression pattern of SOX10 during development is highly dynamic, beginning in NC stem 
cells, being maintained during migration while it is lost upon differentiation in some cell types 
[37, 43]. SOX10 is known to be an important regulator of melanocyte differentiation by 
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promoting the survival and maturation of melanoblasts [43, 44]. During early development 
SOX10 controls the expression of MITF in the NC and thereby influences the activity of 
several genes crucial for commitment to the pigment cell fate and melanogenesis [45]. 
Importance of SOX10 expression during development and maintenance is shown as 
dysregulation of SOX10 is associated with Waardenburg syndrome type 4 [46].  Moreover, 
SOX10 transactivates DCT to stimulate its full activation together with MITF [47].  
 LEF1 
Signaling via the WNT pathway is transduced by the transcription factor Lymphoid-enhancing 
factor-1 (LEF1). LEF1 can act as transcriptional repressor or activator depending on its 
binding partners. By binding to Groucho transcription is suppressed while interaction with 
beta-catenin leads to dissociation of Groucho from the promoter and thereby to initiation of 
transcription [48]. A functional binding site for LEF1 is present in the promoter region of the 
human MITF-M gene. In vitro, binding of LEF1 was confirmed which suggests a role in 
regulating MITF-M expression. Actually, binding of WNT3a to its receptor induces recruitment 
of LEF1 and beta-catenin to the MITF-M promoter and thereby increases transcriptional 
activity of this promoter [27]. Also binding of LEF1 to MITF via the bHLH-LZ region stimulates 
transcription from the MITF-M promoter. Yet, again beta-catenin is necessary for the 
collaborative function of LEF1 and MITF-M [49, 50]. Furthermore, LEF1 and MITF together 
can transactivate the promoter of DCT as well [50]. 
 FOXD3 
The transcriptional repressor FOXD3 is specifically expressed in precursors of neurons and 
glia cells while being absent in cells of the melanocytic lineage. FOXD3 is known to repress 
melanogenesis via MITF. By repressing the expression of MITF, FOXD3 inhibits the 
development of melanoblasts and can prevent migration along the dorsolateral pathway [51, 
52].  
 SCF/KIT and EDN3/EDNRB 
The stem cell factor (SCF)/KIT and the endothelin3/endothelin receptor B (EDN3/EDNRB) 
pathway are the two most important pathways promoting differentiation of NCCs into the 
melanocytic lineage [53]. At several stages in development, KIT plays an important role 
influencing migration and survival. Expression of KIT, as the expression of MITF, starts early 
in premigratory cells and is still present in migrating melanocytes [54]. EDN3 is involved in 
several functions such as migration, proliferation, survival and differentiation of melanocytes. 
It is already required very early in development for melanoblast migration. Expression of TYR 
is stimulated by EDN3/EDNRB signaling [55].  
 
Introduction 
7 
V.3.2. Signaling network in melanocyte development 
As already indicated the cooperation of transcription factors during development is crucial for 
predetermination and full differentiation. MITF, the central factor in melanocyte differentiation 
interacts with several other factors, regulates their expression and is also regulated by 
several factors itself [56]. MITF expression can be stimulated via activation of the WNT 
signaling pathway. After translocation of beta-catenin into the nucleus, beta-catenin and 
TCF/LEF bind to the MITF promoter. In addition, both factors promote transcription of DCT 
[27, 50]. Binding of SCF to its receptor c-KIT results in the activation of MITF via the mitogen 
activated protein kinase (MAPK) pathway [54]. Further, cAMP is known to promote MITF 
expression via CREB, which is dependent on SOX10. Levels of cAMP can be increased by 
interaction of alpha-melanocyte-stimulating hormone (α-MSH) and melanocortin1 receptor 
(MC1R). [57]. Additionally, SOX10 and PAX3 synergistically bind to the MITF promoter and 
activate its transcription [31, 56, 58]. Activation of MITF leads to transcription of the 
melanogenic enzymes TYR, TYRP1 and DCT. Yet, also inhibitory factors are present which 
repress MITF expression. For example FOXD3 prevents MITF transcription by binding to 
PAX3 and thereby inhibiting its binding to the MITF promoter [52]. Further, a cross-regulatory 
interaction of MITF and SOX2 was suggested [59]. SOX2 could repress MITF and if SOX2 
was absent MITF was expressed. On the other hand, ectopic expression of MITF led to 
suppression of SOX2. While PAX3 has a repressive function on DCT expression beta-
catenin can end this suppression by inhibiting PAX3 [30]. For full activation of DCT 
synergistic binding of MITF and SOX10 is necessary [47]. SOX10 is also involved in the 
activation of TYR [60]. A schematic overview of the signaling network is given in Figure 1. 
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Figure 1: Signaling network in melanocytes for transcriptional activation of MITF and induction 
of melanogenesis. MITF is regulated by a variety of signaling pathways and factors. The main 
pathways include activation of MAPK by SCF/KIT, MC1R signaling via cAMP and CREB, WNT 
signaling via LEF1 and beta-catenin and EDN3/EDNR. Additional transcription factors, which are 
activating expression of MITF, are PAX3, SOX9, SOX10 and MITF itself. Negative regulation of MITF 
is induced by SOX2 and FOXD3. SOX2 directly suppresses MITF while FOXD3 functions via inhibition 
of PAX3 binding to the MITF promoter. MITF functions as key transcription factor inducing the three 
melanogenic enzymes TYR, DCT and TYRP1. Besides MITF, SOX10 can activate DCT and TYR. 
PAX3 represses DCT expression. Yet, this repression can be abolished by beta-catenin. 
 
V.4. Melanocyte characteristics 
Depending on the location, melanocytic cells possess unique functions and characteristics. 
In the inner ear melanocytes are essential for normal hearing by generating action potentials 
and play an important role in balance [61, 62]. Melanocytes present in the heart are 
suggested to have anti-inflammatory functions due to their reactive oxygen species (ROS) 
reducing activity [63]. The production of melanin in the brain, so called neuromelanin, 
protects the neurons by controlling ROS levels and reducing toxic compounds [64]. Besides 
that, melanocytes in the brain have neuroendocrine functions being involved in the regulation 
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of sleep and respiration [65]. However, the main and best-known function of melanocytes is 
the production of melanin, which is stored in specialized organelles called melanosomes [66]. 
V.4.1. Melanogenic enzymes 
Several factors are involved in the synthesis of melanin, also known as melanogenesis 
whereby the three melanogenic enzymes, tyrosinase (TYR), dopachrome tautomerase (DCT) 
and tyrosinase-related protein 1 (TYRP1), play crucial roles [67]. Despite the high homology, 
each of them harbors its distinctive functional enzymatic activity. The enzymes regulate 
specific steps in the production of melanin, catalyzing different reactions [68, 69]. 
 Tyrosinase 
The rate-limiting enzyme in melanogenesis is TYR, a transmembrane copper glycoprotein 
which is essential for the initial steps of this process [70, 71]. The general structure and the 
active sites of this enzyme are highly conserved and it is expressed ubiquitously throughout 
the phylogenetic tree. First, it hydrolizes tyrosine to L-3,4dihydroxyphenylalanine (DOPA) 
and further oxidizes DOPA to DOPAquinone, which by itself oxidizes to DOPAchrome 
(Figure 2). The concentration and activity of tyrosinase is dependent on several factors such 
as UV radiation and stabilization by DCT and TYRP1 [70, 71]. In addition, the activity of 
tyrosinase influences the type of melanin produced. High tyrosinase activity results in 
eumelanin production while under low tyrosinase activity pheomelanin is generated. 
Mutations in the TYR gene result in Oculocutaneous albinism type 1 (OCA1) [72], a disease 
which is characterized by hypopigmentation of hair and skin as well as distinct ocular 
changes. 
 Dopachrome tautomerase 
DCT, a type I membrane protein, is a member of the tyrosinase-related protein family and 
displays high homology to tyrosinase. Yet, instead of two copper ions in the catalytic center 
DCT harbors a zinc atom [73]. In contrats to TYR and TYRP1, DCT is already detectable in 
melanoblasts and therefore represents a melanoblast marker [22]. It catalyzes the 
conversion of DOPAchrome to 5,6-dihydroxyindol-2-carboxylat (DHICA) [68] (Figure 2). 
Mutations in the DCT gene can lead to variations in hair color by affecting the melanin 
synthesis [74].  
 Tyrosinase-related protein 1 
The membrane protein TYRP1 is the most abundant glycoenzyme exclusively expressed in 
melanocytes. The function of this enzyme is not completely understood, but it is supposed to 
harbor enzymatic activity [75, 76]. Yet, also the stabilization of TYR and the modulation of its 
catalytic activity were identified as main functions of TYRP1 [77]. Additionally, TYRP1 could 
influence the appearance of melanosomes [78]. Some mutations in the TYRP1 gene lead to 
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Oculocutaneous albinism type 3 (OCA3) [67]. Due to most of the mutations, however, a 
nonfunctional short version of the protein is produced resulting in hypopigmentation of skin, 
hair, and eyes [79].  
 
V.4.2. Melanogenesis and melanin types 
During the process of melanogenesis the pigment melanin is produced. Two types of 
melanin exist in the skin. Eumelanin is the brown or black melanin while pheomelanin is the 
red or yellow type [80]. Eumelanin is the most abundant melanin. It is a heterogeneous 
composition of 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
forming a complex polymer containing nitrogen. Pheomelanin is also a nitrogenous polymer 
but mainly consists of 1,4-benzothiazine units which contain sulfur [81] (Figure 2). Melanin is 
produced and stored in melanosomes, which are specialized lysosome-related organelles 
found in pigment cells. These cytoplasmic vesicles contain the melanogenic enzymes TYR, 
TYRP1 and DCT. Two types of melanosomes exist according to the types of melanin 
produced: eumelanosomes contain the brown or black eumelanin and pheomelanosomes 
contain the red or yellow pheomelanin [82, 83]. Depending on the type, the organelles have 
an elliptical or spherical appearance, respectively. Typical for eumelanosomes is the fish net-
like appearance. Intraluminal fibrils, mostly consisting of the transmembrane glycoprotein 
PMEL, are formed in premelanosomes that also influence the shape of the melanosome. 
During maturation, melanin accumulates on these fibrillary structures. Pheomelanosomes do 
not possess such fibrils and therefore have various shapes but are mostly round with a 
vesiculo-globular lumen [82, 84]. The distribution and amount of melanosomes determine the 
pigmentation of the skin. In dark pigmented skin high concentrations of eumelanosomes are 
present while only a few pheomelanosomes can be found.  
Melanosome development can be divided into four stages. In stage I the melanosomes 
resemble multivesicular endosomes with luminal vesicles within an amorphous matrix. In this 
stage, matrix organization is initiated. In stage II, the matrix of eumelanosomes is organized 
in structured proteinaceous fibrils but melanin synthesis is not activated, yet. In contrast, 
melanin formation has started in pheomelanosomes already at this stage. Melanin deposition 
on the fibrils takes place in stage III. The matrix of melanosomes is fully melanized in stage 
IV [83]. 
The amount of free melanosomes in the epidermis is much higher in dark pigmented skin as 
well. Moreover, melanosomes are bigger and mostly present in mature stages [85]. UV 
exposure stimulates the transport of melanosomes inside the melanocytes along actin and 
microtubule filaments to the tips of the dendrites. Subsequently melanosomes are transferred 
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to the surrounding keratinocytes for UV protection preventing DNA damage and reducing 
skin cancer risk [83]. 
Different factors influence the type of melanin. In addition to the abundance and the activity 
of the melanogenic enzymes, especially tyrosinase, the melanocortin 1 receptor (MC1R) is a 
main factor determining eu- or pheomelanogenesis. Signaling via the MC1R favors 
generation of eumelanin due to stimulation of tyrosinase. Under low tyrosinase activity 
pheomelanin synthesis is favored, since only low amounts of L-dopaquinone are generated 
which are almost entirely used up for pheomelanin synthesis due to higher concentration of 
thiol compounds and the resulting conjugation of these two molecules [86]. Also other factors 
such as sulfur compounds, cytoplasmic cAMP level, WNT signaling and MAPK signaling can 
influence melanogenesis [71]. While eumelanin is thought to have a UV protective function 
[87] pheomelanin favors the production of reactive oxygen species which promotes 
melanomagenesis, thus the development of melanoma [88, 89]. 
 
Figure 2: Simplified scheme showing parts of the melanin synthesis. The initial step of melanin 
synthesis is the conversion of tyrisone to DOPA and further to DOPAquinone. DOPAquinone can be 
converted into DOPAchrome leding to eumelanin production. Addition of cysteine to DOPAquinone 
leads to pheomelanin synthesis. 
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V.5. Skin Cancer 
Skin cancer is the malignancy with the highest incidence in the US and Germany as well as 
many other countries with weakly pigmented populations [90]. Skin cancer can be divided 
into two main subtypes: Melanoma and non-melanoma skin cancer. 
V.5.1. Non-melanoma skin cancer 
The most common types of non-melanoma skin cancers include basal cell carcinoma (BCC) 
and squamous cell carcinoma (SCC) which originate from dysregulated keratinocytes. About 
75% of non-melanoma skin cancers are BCCs mostly arising at sun exposed areas [91]. 
Basal cells, non-keratinizing cells located in the deepest layer of the epidermis, undergo 
malignant transformation in this cancer type. Although these cells rarely spread to form 
metastases appropriate treatment is essential to prevent severe morbidity [92]. SCCs arise 
from keratinocytes residing in the epidermis and account for about 20% of the diagnosed 
non-melanoma skin cancers [93]. The development of SCC can also be correlated to sun 
exposure. As BCCs, SCCs usually do not form metastases. However, if they spread they 
migrate deep into the skin and can also gain access to the lymph nodes and proximal organs 
to form secondary tumors [92]. Rare types of non-melanoma skin cancers are Merkel cell 
carcinoma, cutaneous lymphoma, and Kaposi sarcoma which all together make up 1% of all 
non-melanoma skin cancers [93, 94]. 
V.5.2. Melanoma 
Melanoma arises from melanocytes and can develop from abnormal moles. It is an 
aggressive skin cancer with high mortality rates for patients in advanced stages. Only about 
2% of all skin cancers are melanomas yet it accounts for the majority of skin cancer related 
deaths in the US. The five year survival rate today lies at 98% for local malignancy in 
contrast to 63% and 16% if the cancer has metastasized to regional or distant areas, 
respectively [95]. Melanoma can be categorized into different subtypes. The three most 
common types, superficial spreading melanoma, nodular melanoma, and lentigo maligna 
melanoma, together account for 90% of melanomas diagnosed. The other 10% are acral 
lentiginous melanoma and other rare types [96]. The prognosis of the patient depends on the 
depth of invasion. Different staging systems can be used to estimate the stage of the patient. 
Today the Breslow scale and the mitotic rate of the primary tumor are considered most 
commonly. The thickness of the melanoma is measured by the Breslow scale [97]. The 
mitotic rate, which is determined histologically by the amount of mitosis per mm2, is a 
measure for overall survival. Increased mitotic rates correspond to declined survival [98]. 
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 Genes involved in melanoma and SCC pathogenesis 
Cancer development and progression can mostly be correlated with specific signaling 
pathways or distinct genes that are differentially regulated. Tumor promoting genes, also 
known as oncogenes, are often highly activated while tumor suppressor genes which can 
prevent tumor formation are downregulated or lost in cancer cells [99]. These changes in 
expression can be due to chromosomal aberrations, mutations or epigenetic modulations 
[100]. Certain pathways and genes have also been associated with the formation of SCC and 
melanoma. 
  Differentially regulated genes in SCC 
In squamous cell carcinoma high rates of mutations in the tumor suppressor gene TP53 have 
been described. As the ‘guardian of the genome’ p53 is activated upon DNA damage, 
controls cell cycle progression and induces apoptosis. It is the most frequently mutated gene 
in SCCs with an incidence of 54%-69%. Already more than 50% of premalignant lesions 
carry this mutation [101, 102]. UV radiation causes the typical C-T transition mutation, which 
was detected at the TP53 locus in many actinic keratosis (AK) lesions, and SCCs. Mutations 
were mostly found in exon 5, 6, 7 and 8. Specifically codons 177,179 and 241 were the hot 
spots in aggressive SCCs. [101, 103]. Thus, mutations in TP53 probably occur early in SCC 
development and UV exposure seems to play a crucial role in this process. 
Additionally oncogenes are involved in the initiation and progression of SCC. For example, 
various mutations in the RAS gene have been described for SCC. These mutations lead to 
constitutive activation of the downstream signaling pathway resulting in uncontrolled 
proliferation due to cell cycle progression and resistance to apoptosis [104]. HRAS is 
commonly mutated by a substitution of glycine with valine at codon 12 (G12V). Additional 
RAS family members KRAS and NRAS are mutated less frequently in SCCs [105]. Yet, in AK 
mutations of HRAS or KRAS were reported at a frequency of 16%. Presence of these 
mutations in SCC precursor lesions indicates that RAS might be involved in the initiation of 
SCC [106].  
 Differentially regulated genes in melanoma  
Altered signaling pathways accompany malignant cell transformation of melanocytes leading 
to melanoma formation. Growth factors become activated leading to uncontrolled 
proliferation accompanied by anti-apoptotic signaling and tumor suppressor inactivation. 
Prominent pathways known to be involved in melanoma initiation and progression are the 
classical MAPK or phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) signaling 
pathway. Classical oncogenes in melanoma are BRAF and NRAS. BRAF was found to be 
mutated leading to activation in most melanomas. Over 66% of these mutations result in a 
substitution of valine with glutamic acid at position 600 (V600E) leading to the activation of 
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the MAPK pathway [107]. NRAS is able to activate both, the MAPK pathway and the PI3K-
AKT pathway as well [108]. BRAF and NRAS mutations are commonly found in the 
premalignant lesions of melanoma, so called melanocytic nevi, already [109, 110]. The BRAF 
V600E mutation was found in 18 out of 22 melanocytic nevi investigated. Mutations at codon 
61 of NRAS were observed in three melanocytic nevi [109]. 
In addition to activation of oncogenes also loss of tumor suppressors can promote 
melanomagenesis. High expression of CDKN2B leads to growth arrest in nevus melanocytes 
and keeps these cells in a premalignant state. The loss of CDKN2B promotes to progression 
from benign melanocytic nevus to melanoma [111].  
 
V.6. Transdifferentiation 
Transdifferentiation is the direct conversion of one differentiated cell into another. During this 
process the cells acquire the phenotype of another cell type while losing the characteristics 
of the original one. This phenomenon is a subclass of metaplasia, which also includes 
switching of stem cells from one tissue type into another [112, 113]. 
V.6.1. Cell fate conversion 
During embryonic development pluripotent stem cells differentiate into several distinct cell 
types of various tissue. Thereby their differentiation potential is reduced and they become 
committed unipotent cells of a certain lineage. The differentiation process was considered to 
be a unidirectional path which cannot be reversed. Waddington’s epigenetic landscape 
model illustrated the concept of cell differentiation and lineage commitment [114]. The 
undifferentiated pluripotent cell is located above the somatic cells that are differentiated and 
specified to a certain lineage. When cells start to differentiate they are like ‘a marble rolling 
down a hill’, ending up in a certain valley representing final cell fate. However, advances in 
the stem cell field through generation of pluripotent cells by cell nuclear transfer [115], cell 
fusion [116], and reprogramming via ectopic expression of transcription factors [117] led to a 
paradigm shift. Cell differentiation can be reverted using different methods and is thus not a 
unidirectional process. Additionally, dedifferentiation into a precursor cell and 
transdifferentiation, the direct cell fate conversion from one somatic cell into another, was 
achieved (Figure 2). Already decades ago it was shown that the transcription factor MyoD 
(myoblast determination) can convert fibroblasts into muscle-like cells [118]. Following this, 
several direct conversions of closely related cells from the same germ layer have been 
reported [119-122]. More recently, even fibroblasts from the mesoderm could be 
transdifferentiated into ectoderm-derived neurons. This conversion between different germ 
layers was achieved by a combination of only three transcription factors: Ascl1, Brn2 and 
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Myt1l [123]. In addition to reprogramming this was another proof that ectopic expression of 
specific transcription factors is sufficient to change the cell fate of a committed cell. 
 
Figure 3: Cell fate conversion. Generation of pluripotent cells can be achieved by reprogramming of 
cells for example via ectopic overexpression of transcription factors. Dedifferentiation is the conversion 
into a precursor cell. Transdifferentiation is the direct switch from one differentiated cell type into 
another 
V.6.2. Origin and definition of transdifferentiation 
Transdifferentiation describes the (direct) conversion of one differentiated cell type into 
another [112, 113]. In nature, transdifferentiation occurs as a two-step process. The cells 
dedifferentiate first, start proliferating again and then differentiate into another cell type. One 
example is the regeneration of the newt lens [124]. Pigmented epithelial cells depigment and 
generate a dedifferentiated intermediate cell population, which can subsequently 
redifferentiate into primary lens fibers expressing crystalline. True transdifferentiation is 
defined by two criteria established by Eguchi and Okada. First of all, establishment of a 
lineage relationship between the two cell types is necessary. Secondly, cell types need to be 
easily distinguishable from each other. Changes in cell morphology alone are insufficient to 
proof transdifferentiation. Additionally, differences on the molecular level must be present 
[125, 126] .  
Experimental transdifferentiation, in contrast to natural transdifferentiation, is thought to be a 
direct process possibly with an unnatural intermediate state [127]. Often transcription factors 
known to play an important role in the development of the cell type of interest are used for 
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conversion. Ectopic expression of these factors activates the endogenous transcriptional 
program distinctive of the cell type, which should be generated. At the same time markers 
specific for the original cell type are downregulated. For example, CCAAT-enhancer-binding 
protein-alpha (CEBPα), a transcription factor inducing macrophage differentiation, can 
convert B cells into macrophages. During this transdifferentiation B cell markers such as 
PAX5 and CD19 are downregulated while MAC1, a gene specifically expressed in 
macrophages, is upregulated [119].  
V.6.3. The role of epigenetic modifiers in cell fate conversion 
Not only transcription factors but also epigenetic remodeling factors play an important role in 
cell type conversion. Changes in the epigenetic landscape during normal development 
stabilize cell fate and lineage determination [128-130]. Extreme changes in the epigenetic 
pattern also occur during reprogramming. Specific histone modification and demethylation 
can favor reprogramming. Treatment with the histone deacetylase inhibitor valproic acid 
(VPA) or 5-aza-cytidine (AZA), a DNA methyltransferase inhibitor promotes transition into a 
pluripotent state [131, 132]. The use of VPA allows reprogramming of human fibroblasts with 
only SOX2 and OCT 4. The two oncogenes c-MYC and KLF4 are not necessary for induction 
of the stem cell state [133]. Interplay between transcription factors known to be related to 
specific cell fates and epigenetic remodelers was suggested to be necessary for solid 
transition. Two specific methylation marks, histone 3 lysine 27 (H3K27) and histone 3 lysine 
4 (H3K4) were identified to control reprogramming towards pluripotency [134, 135]. 
Epigenetic alterations were also detected during transdifferentiation. These changes are 
necessary for stable transdifferentiation in vivo and in vitro [136]. 
V.6.4. Purpose of studying transdifferentiation 
Transdifferentiation is an interesting phenomenon to study for several reasons. First, 
investigating transdifferentiation will lead to a better understanding of the normal embryonic 
development since it will uncover key factors, including transcription factors, which are 
essential for the determination and differentiation of certain lineages. Moreover, identification 
of such key factors will help to understand the interplay between them providing insights into 
regulatory mechanisms and the hierarchical structure of transcription factor networks during 
development [137].  
Secondly, advances in transdifferentiation could be used in regenerative medicine for cell 
replacement therapy. Specific cell types could be directly generated from patient cells. In 
several diseases cells are lost or damaged and cannot be replaced by the body itself. For 
example in type I and type II diabetes, the loss of functional β-cells leads to lack of insulin or 
insulin resistance, respectively [138, 139]. In 2008, Zhou and coworkers identified a 
transcription factor combination which transdifferentiated exocrine cells from the pancreas 
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into cells very similar to endocrine β-cells. These cells could produce and secrete insulin and 
thereby improve hyperglycemia in diabetic mice [120]. Other examples for diseases that 
could be treated by cell replacement therapy are neurodegenerative diseases like 
Parkinson’s disease or Huntington’s disease. For Parkinson’s disease advances have been 
made in identifying the factors, which effectively generate dopaminergic neurons, by 
transdifferentiation [140]. 
Thirdly, transdifferentiation and metaplasia are closely related processes. Metaplasia is the 
abnormal transformation of one cell type into another, which is unusual for the type of tissue. 
Probably the best known example for metaplasia is the Barrett’s metaplasia [141]. This 
transformation is suggested to predispose for cancer development. Therefore studying 
transdifferentiation can yield important information about tumor initiation and progression 
[137]. 
Finally, transdifferentiation has several advantages in comparison to reprogramming cells to 
pluripotency. Firstly, transdifferentiation is supposed to be faster and more efficient than 
reprogramming. To generate the cell type of interest via reprogramming the cells have to be 
dedifferentiated to create induced pluripotent stem cells (iPSCs). Thereupon, the cells then 
need to be redifferentiated. This procedure is time consuming and inefficient [142]. In 2013, 
Hanna and colleagues claimed to have increased the reprogramming efficiency to almost 
100% by knocking out Mbd3, a core member of the Mbd3/NuRD (nucleosome remodelling 
and deacetylation) repressor complex. [143]. Yet, most of the established protocols used can 
convert cells much less efficiently. Transdifferentiation however, yields efficiency from up to 
25% depending on the cell type [144, 145]. In addition, although iPSCs imply extensive 
clinical application, the potential is limited because of the possibility of tumor formation after 
transplantation. Due to their high differentiation potential, iPSCs can form teratomas, benign 
tumors of various tissue types, upon injection. These teratomas can gain malignant 
characteristics [146, 147]. Additionally, the expression of the oncogene c-MYC, which is used 
for reprogramming, could induce tumor formation [148].  Transdifferentiated cells do not 
harbor this risk because differentiated cells with limited differentiation potential are generated 
via this method. Further, only factors favoring the targeted differentiation are used which 
usually do not include oncogenes. 
V.6.5. Progress in the field of transdifferentiation  
Transdifferentiation has been intensively studied in the last few years. Many advances have 
been made and various cell lines could be generated by either intra-germ layer 
transdifferentiation from cells closely related but also transdifferentiation across germ layers 
was achieved. A recent comprehensive overview is given in the review by Xu and colleagues 
[149]. 
Introduction 
18 
 Intra-germ layer transdifferentiation 
Within the mesoderm fibroblasts have been converted into cardiomyocytes and muscle cells. 
The factor combination GATA4, MEF2C and TBX5 was identified to generate cardiomyocyte-
like cells [150]. For induction of cardiomyocytes in vivo the additional factor HAND2 was 
necessary [151]. Another example for transdifferentiation within the mesoderm is the cell fate 
switch from B cells and T cells into macrophages by either using the single factor CEBPα or 
CEBPβ [119]. The transcription factor PU.1 was sufficient to achieve dendritic cells from T 
cells progenitors [152]. 
Induction of pancreatic β-cells in vivo is the most prominent example for transdifferentiation 
of cells within the endodermal lineage. In this example, the transcription factor combination 
NGN3, PDX1 and MAFA was expressed in exocrine cells from the pancreas. However, the 
efficacy of this combination seemed to be cell type specific since fibroblasts could not be 
converted using these factors [120]. Different neural subtypes have been generated by 
transdifferentiation more than 10 years ago. The expression of the transcription factors 
PAX6, ASCL1, NGN2 or DLX2, or combined expression in astrocytes led to the induction of 
neuronal cell fate [121, 153, 154].  
 Transdifferentiation across germ layers 
After the break through study of Wernig and colleagues in 2010 several cell types have been 
generated across germ layers mostly by the conversion of murine or human fibroblast using 
a defined combination of transcription factors [123]. Besides converting fibroblasts into 
mature neuronal cells using ASCL1, BRN2 and MYT1L also neural stem cells were 
generated [155], representing transdifferentiation from cells of the mesoderm into ectodermal 
cell types. Transdifferentiation of mesodermal cells to endodermal cells has been achieved 
by the induction of hepatocytes from fibroblasts. Two different studies describe this process. 
The transcription factors GATA4, HNF1α and FOXO3 combined with the knockout of p19Arf 
[156] or FOXA1, FOXA2, FOXA3 with HNF4α were sufficient to induce hepatocyte cell fate 
[157]. 
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Table 1: Overview of examples for transdifferentiation 
Initial cell type Target cell type  Transcription factors 
Fibroblasts Cardiomyocytes GATA4, MEF2C, TBX5 
B cells and T cells Macrophages CEBPα or CEBPβ 
T cells Dendritic cells PU.1 
Pancreatic acinar cells Pancreatic β cells NGN3, PDX1, MAFA  
Astrocytes Neurons PAX6, ASCL1, NGN2 or DLX2 
Fibroblasts Neurons ASCL1, BRN2,MYT1L 
Fibroblasts Hepatocytes GATA4, HNF1α, FOXO3, knockout of p19Arf  
Fibroblasts Hepatocytes FOXA1, FOXA2, FOXA3 with HNF4α  
 
V.6.6. Generation of melanocytes  
Melanocytes can be found in several tissues of the body such as the eye, the inner ear, the 
hair bulge, the central nervous system and the skin. The main function of melanocytes is the 
production of pigment in the skin upon exposure to UV light and transfer to keratinocytes 
thereby preventing DNA damage in skin cells. Various pigmentary disorders have been 
described which are due to defects or loss of melanocytes [158]. Depigmentation of the skin 
due to loss of melanocytes (Vitiligo), for example, could be treated by transplantation of 
autologous melanocytes. Yet, clinical application is very low due to several drawbacks [159]. 
Thus, there is a need for an easily accessible source of patient-specific melanocytes. 
 Guided differentiation of stem cells into melanocytes 
Generation of melanocytes was demonstrated for the first time by differentiation of murine 
embryonic stem cells (ESCs) in coculture with the stromal cell line ST2. The induction of 
melanocytes was dependent on the presence of steel factor and the efficiency could be 
enhanced by the addition of dexamethasone. At day 6 in culture, ESC colonies were visible. 
Between day 12 and day 13 some cells changed their morphology into spindle shaped 
dendritic cells and migrated out of the colonies. Expression of c-KIT and other melanocyte 
markers was detected. After 21 days the majority of the cells had turned into mature and fully 
pigmented melanocytes [160]. 
In 2006, Fang and coworkers achieved the differentiation of human ESCs into melanocytes. 
This differentiation process took 4-6 weeks. WNT3a, EDN3 and SCF were necessary for the 
induction of the melanocytic phenotype. Expression of the melanocyte markers MITF and 
TYR was activated and melanosomes filled with melanin were present in the cells. The 
transition was stable even after culture of these cells over a longer time and after 
transplantation into skin reconstruction. WNT3a was identified to be essential for induction of 
MITF and pigmentation of the cells. Reduction of WNT3a concentration caused a delay in 
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differentiation. The combination of WNT3a and EDN3 was sufficient for melanocyte cell fate 
induction. Additional factors which were added to the medium enhanced differentiation. A 
certain degree of differentiation could be achieved by growth factors alone. Yet, WNT plays 
an important role for the survival of NC progenitors. In conclusion, determination of the cell 
fate depends on the synergistic interplay of several factors [161].  
Dermal stem cells (DSC) could be differentiated under the same conditions. Dendritic cells 
expressing melanocyte markers (MITF, DCT, S100, HMGB45) were generated. Culture of 
DSC in differentiation medium for two to three weeks was necessary to generate this 
phenotype. When transplanted into 3D skin reconstructs differentiated melanocytes settled 
on the basal membrane just like normal melanocytes. Melanocytic characteristics could also 
be induced by seeding DSC on skin reconstructs. Cells migrated into the epidermis and 
activated the melanocyte differentiation program [162]. 
IPSCs generated by three or four factors were differentiated into melanocytes by WNT3a, 
SCF, and EDN3. Using iPSCs circumvents the ethical issues connected to ESCs. 
Additionally, patient cells can be used for generation of the cell type of interest. First, 
embryoid bodies (EBs) were formed which were transferred to melanocyte differentiation 
medium containing WNT3, SCF, EDN3, cholera toxin (CT) after three weeks. Single cells 
were observed after one week under these culture conditions and pigmented cells were 
present after another 3-4 weeks. Melanocyte marker expression was activated and 
melanosomes were present as well. Additionally, these cells had lost their proliferative 
capacity which is also a typical characteristic for human melanocytes [163]. 
A cocktail of various cytokines was used in the previously described differentiation protocols 
to induce the melanocyte phenotype. Additionally, formation of EBs was necessary for 
dendritic cells to appear in culture. Nissan and colleagues described an elegant way to 
produce melanocytes from ESCs and iPSCs by only one factor. With a gradient of BMP-4 
pigment cells (retinal pigment epithelium (RPE) and melanocytes) could be created from 
hESCs and iPSCs. Hereby it was possible to discretely investigate the different stages during 
development into mature cells. High concentration of BMP-4 induced the generation of 
epithelium and keratinocytes, while low concentrations were needed for neural cell 
differentiation. Using a BMP-4 gradient two subpopulations of pigment cells arose: RPE-like 
cells and bipolar cells expressing PAX3. The bipolar cells were further cultivated and after 
four passages melanocytes had developed. The gene expression profile resembled the one 
of melanocytes and the cells were positive for several melanocytic markers. Moreover, also 
melanosomes of all maturation stages were detected. Under coculture conditions with 
keratinocytes transfer of melanosomes could be observed. The generated melanocytes were 
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proven to be fully functional since they were able to cause pigmentation of cells in 3D skin 
reconstructs [164]. 
 Transdifferentiation of fibroblasts into melanocytes 
Tachibana and colleagues identified MITF as a critical factor in melanocyte differentiation. 
Morphological changes were induced in NIH3T3 mouse fibroblasts by ectopic expression of 
MITF. These cells adapted a dendritic morphology and expressed melanocyte markers and 
exhibited immature melanosomes in their cytoplasm. Yet, no synthesis of melanin could be 
noted, probably due to the mutated form of tyrosinase present in the parental cells. Therefore 
the generated cells resembled amelanotic melanocytes [165]. 
Recently, functional melanocytes have been generated from murine and human fibroblasts 
with a defined factor combination. After screening ten candidate factors, the three factor 
combination MITF, SOX10 and PAX3 has proved to be sufficient to activate the expression 
of several melanocyte markers and induce melanogenesis. In a 3D skin reconstruct as well 
as in vivo, the induced melanocytes were able to localize at the dermal-epidermal junction 
and transferred the produced melanin to neighboring keratinocytes. While murine fibroblasts 
changed their morphology after 14 days of induction and G418 selection, 40 days in culture 
were necessary for transdifferentiation of human cells with an efficiency of 40%. Marker 
expression was detected after 80 days. At day 100, 99.3% of the cells stained positive for 
TYR. The phenotype was stable and independent of transgene expression. Remarkably, 
conversion of adult human fibroblasts was much less efficient than conversion of fetal 
fibroblasts [166].  
V.6.7. Transdifferentiation of cancer cells 
In 2013, cancer cells have successfully been transdifferentiated by Thomas Graf’s group. B 
lymphoma and leukemia cell lines were converted into macrophages via expression of the 
transcription factor C/EBPα. After induction cells downregulated B cell markers and 
expressed macrophage markers instead. Increased adherence, granularity and cell size was 
noted. Additionally, high phagocytic activity could be demonstrated. The induction also 
impaired the tumorigenic potential of these cells which was shown by injection into 
immunodeficient mice [167]. 
 
 Correlation between tumorigenic potential and cell lineage 
Recent studies suggest that the ability of cancer cells to form a tumor depends on the 
differentiation lineage. Reprogramming of cancer cells with subsequent differentiation into 
several cell types led to impairment of the tumor formation [168]. Also differentiation of so 
called cancer stem cells was efficient to repress the tumor phenotype [169]. Thus, 
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conversion of one cell type into another differentiation lineage could abrogate the tumorigenic 
potential of the cells. However, probably not only the conversion of cancer cells into another 
lineage underlies this phenomenon. Also terminal differentiation into postmitotic cells might 
have a crucial influence on the impairment of tumorigenicity. Generation of mature red blood 
cells and terminally differentiated connective tissue from sarcoma cells caused loss of 
tumorigenic potential of these cells. The suggested underlying mechanism is extensive 
epigenetic remodeling. It is known that differentiation is associated with epigenetic changes 
stabilizing the differentiation phenotype. Zhang and colleagues could show that 
reprogramming of cells into a dedifferentiated state is accompanied by significant epigenetic 
changes especially of tumor suppressor genes and oncogenes [168]. 
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VI. Aims of the thesis 
 
During development, lineage-specific transcription factors determine the cell fate. The 
ectopic overexpression of specific transcription factors was used for cell fate conversion. 
Several studies showed that distinct transcription factors can promote the transdifferentiation 
of one somatic cell type into another. Even the lineage of origin of cancer cells could be 
switched by this mechanism resulting in impaired tumorigenic potential. By directly converting 
cancer cells into other somatic cells, the mechanism by which normal cells turn into cancer 
cells can be better understood and the characteristics which are linked to the tumorigenic 
phenotype might be identified. This approach might additionally lead to an alternative 
therapeutical strategy for the treatment of cancer.  
The aim of this project is to transdifferentiate tumor cells from the keratinocytic lineage into 
functional and potentially non-tumorigenic cells from the melanocytic lineage. We 
hypothesize that the tumorigenic potential of a cancer cell is dependent on the differentiation 
lineage. Thus, transdifferentiation of squamous cell carcinoma cells (SCCs) into the 
melanocytic lineage should yield non-tumorigenic cells.  
The following research questions were addressed to test this hypothesis: 
1.) Can SCCs be transdifferentiated into melanocyte-like cells by ectopic overexpression 
of a defined set of transcription factors? 
 
2.) If so, have the resulting cells lost their tumorigenic potential? 
 
3.) What is the mechanism behind the conversion into non-tumorigenic cells? 
 
To answer these questions a transcription factor pool containing 21 factors was screened for 
the minimal combination of transcription factors necessary to convert SCC cells into 
melanocyte-like cells. Further, functional assays analyzing characteristics related to a 
malignant phenotype were performed with the transdifferentiated cells and their tumorigenic 
potential was investigated in vivo. Genetic alterations were investigated and the methylation 
landscape and the whole genome expression were analyzed via a gene set enrichment 
analysis to identify putative mechanisms responsible for the loss of tumorigenic potential 
upon transdifferentiation. 
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VII. Materials and Methods 
VII.1. Materials 
Table 2: Reagents and kits 
Reagents and kits Company 
AlamarBlue Invitrogen 
Amersham ECL Prime Western Blotting Detection Reagent GE Healthcare 
Ammonium Persulfate Solution (APS) Carl Roth 
Ampicillin Carl Roth 
Apo-ONE® Homogeneous Caspase-3/7 Assay Promega 
Arcturus PicoPure RNA isolation Kit Applied Biosystems 
BrdU cell proliferation ELISA Abcam 
Calcium chloride  Carl Roth 
cOmplete Mini Protease Inhibitor Cocktail Roche Diagnostics 
Cultrex 24 well BME Cell Invasion Assay Trevigen 
DH5α competent cells Invitrogen 
DNeasy Blood & Tissue Kit Qiagen 
dNTP Bioron 
Ethanol Sigma-Aldrich 
Human IL-24 ELISA Cusabio 
HumanCytoSNP-12 Illumina 
HumanHT-12 v4 Expression BeadChip Kits Illumina 
Ibidi Culture-Insert 500 µm ibidi 
Immobilion PVDF membrane pore size 0.45 µm Merck Millipore 
Infinium HumanMethylation450 BeadChip Kit Illumina 
Isopropanol Sigma-Aldrich 
LB (lysogeny broth) medium Carl Roth 
Methanol  Sigma-Aldrich 
Phenol chloroform Sigma-Aldrich 
Phosphate buffered saline (PBS)  Biochrom 
PhosphoStop Phosphatase Inhibitor Cocktail Roche Diagnostics 
Phusion polymerase Thermo Scientific 
Pierce BCA Protein Assay Kit ThermoScientific 
Plasmid Maxi Kit Qiagen 
Puromycin Carl Roth 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific 
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RNase-free DNase Set Qiagen 
Rotiphorese Gel 30 Carl Roth 
Skim Milk Powder Sigma-Aldrich 
Sodium acetate  Carl Roth 
Sodium dodecyl sulfate (SDS) G-Biosciences 
SYBR Green PCR Master Mix Applied Biosystems 
Tetramethylethylenediamine Carl Roth 
Tween20 Applichem 
X-tremeGene 9 DNA transfection reagent Roche Diagnostics 
Zeocin InvivoGen 
 
Table 3: Cell culture reagents 
Cell culture reagents Company 
β-mercapthoethanol 
Adenine 
Gibco® Life Technologies 
Sigma-Aldrich 
Basic fibroblast growth factor (bFGF)  Promokine 
Bovine pituitary extract (bPE) 
Braunol 
Life Technologies 
Braun 
Dimethylsulfoxide (DMSO)  
Dispase 
Carl Roth 
Sigma-Aldrich 
Dulbecco's Modified Eagle's medium (DMEM) AQmedia TM Sigma-Aldrich 
Doxycyline Sigma-Aldrich 
Fetal Bovine Serum (FBS) Biochrom 
Forskolin 
Human melanocyte growth supplement (HMGS) 
R&D Systems 
Gibco® Life Technologies 
Hydrocortisone Sigma-Aldrich 
Insulin Sigma-Aldrich 
MCDB 153 media (MCDB) 
Medium 254 
Sigma-Aldrich 
Gibco® Life Technologies 
Penicillin/Streptomycin (Pen/Strep) 
Phorbol 12-myristate 13-acetate (PMA) 
Recombinant human insulin-like growth factor-I 
Sigma-Aldrich 
Sigma-Aldrich 
R&D Systems 
12-O-tetradecanoylphorbol-13-acetate (TPA) Sigma-Aldrich 
Trypsin Sigma-Aldrich 
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Table 4: Inhibitors 
Inhibitors Company 
3-Methyladenine  Sigma-Aldrich 
AKT Inhibitor VIII Calbiochem 
Mitomycin C Carl Roth 
 
Table 5: Primary and secondary antibodies 
Primary and secondary antibodies  Company 
Beta-actin Cell Signaling 
DCT ProteinTech 
IL-24 Abcam 
MITF Abcam 
Pan-cytokeratin 
Goat anti-mouse HRP 
Goat anti-rabbit HRP 
Santa Cruz  
Cell Signaling 
Cell Signaling 
 
Table 6: Solution buffers and gels 
Phosphate buffered saline (PBS) pH 7.4 
3.2mM Na2HPO4 
0.5mM KH2PO4 
1.3mM KCl  
Tris buffered saline (TBS) pH 7.6 
137mM NaCl 
20mM Tris 
  
Running buffer pH 8.3 
25mM Tris 
190mM glycine 
0.1% SDS 
  
Laemmli 2x buffer pH 6.8 
4% SDS 
10% 2-mercaptoethanol 
0.004% bromophenol blue 
0.125M Tris HCl 
  
Cell lysis buffer for protein isolation 
1x PhosphoStop 
1x cOmplete Mini Protease Inhibitor Cocktail 
Transfer buffer pH 8.3 
25mM Tris 
190mM glycine 
20% methanol 
 
Washing buffer pH 7.6 
137mM NaCl 
20mM Tris 
0.1% Tween20 
 
Solution buffers and gels 
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1% Triton-X in TBS  
 
Running Gel 
3.3ml H2O 
3ml 30% acrylamide/bisacrylamide solution 
2.5ml 1.5M Tris pH 8.8 
100µl 10% SDS solution 
100µl 10% ammonium persulfate solution 
(APS) 
20µl tetramethylenediamine (TEMED 
Stacking Gel 
3.4ml H2O 
0.83ml 30%acrylamide/bisacrylamide solution 
0.63ml 1M Tris pH 6.8 
50µl 10% SDS solution 
50µl 10% ammonium persulfate solution 
(APS) 
5µl tetramethylenediamine (TEMED) 
 
Table 7: Analysis software 
Analysis software Source 
7500 Software v2.0.5 Applied Bioscience 
ApE  M. Wayne Davis (Open Source) 
BD FACSDivaTM  Biolegend 
Chipster Chipster Open source 
Curve Expert 1.4 Cusabio 
FlowJo 7.2.2. FlowJo 
Gene Set Enrichment Analysis (GSEA) Broad Institute of MIT and Harvard 
Genome Studio Illumina 
GraphPad Prism 5 GraphPad Prism 
iControl 1.10  TECAN 
ImageJ  National Institute of Health (NIH) 
Ingenuity Pathway Analysis Qiagen 
Leica Application Suite v1.8.0 Leica 
NIS-Elements Viewer Nikon 
RnBeads R-Package Max Planck Institute Informatics  Open source 
T-scratch CSElab 
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Table 8: Devices 
 
Table 9: Candidate transcription factors for transdifferentiation 
Candidate transcription factors for transdifferentiation 
MITF-M NFIX 
SOX2 IRF4 
SOX5 ETS1 
SOX9 FOSB 
SOX10 HAND1 
LEF1 HES1 
Beta-catenin HOXB7 
PAX3 IFI16 
SNAI2 KLF9 
cMET PITX1 
TFAP2A  
 
VII.1.1. Plasmids 
TetO-MIR human MITF-M 
 
minimal CMV promoter 2170..2229
TRE 1946..2168
cPPT 1808..1823
RRE 1075..1308
HIV1 Psi packaging element 521..565
HIV1 5'LTR 230..410
F1 ori 6313..6619
LacZ alpha 6226..6294
M13-fwd 6155..6138
T7 6129..6109
HIV1 5'LTR 5541..5721
U3 PPT 5471..5492
cPPT 5471..5486
WPRE 4815..5390
LacO 8859..8881
M13-rev 8887..8907
T3 8925..8944
tetO-MIR-human MITF-M
8967 bp
ColE1 origin 7837..8519
AmpR 7080..7739
RFP 4096..4806
IRES 3523..4095
human MITF-M 2257..3516
Devices Company 
AB 7500 Real Time PCR machine Applied Biosciences 
FACS LSR Fortessa 
Leica DM LS light microscope 
BD Biosciences 
Leica 
NanoDrop ND-1000 Spectrophotometer Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence microscope Nikon 
Nikon Eclipse TS100 microscope Nikon 
TECAN infinite F200 pro microplate reader TECAN 
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Tet-O MIR human LEF1 
 
 
TetO-MIR human SOX10 
 
 
 
 
 
minimal CMV promoter 2170..2229
TRE 1946..2168
cPPT 1808..1823
RRE 1075..1308
HIV1 Psi packaging element 521..565
HIV1 5'LTR 230..410
RFP 4064..4774
F1 ori 6281..6587
LacZ alpha 6194..6262
M13-fwd 6123..6106
T7 6097..6077
HIV1 5'LTR 5509..5689
U3 PPT 5439..5460
cPPT 5439..5454
WPRE 4783..5358
LacO 8827..8849
M13-rev 8855..8875
T3 8893..8912
tetO-MIR-human LEF1
8935 bp
ColE1 origin 7805..8487
AmpR 7048..7707
IRES 3491..4063
human LEF1 2268..3467
minimal CMV promoter 2170..2229
TRE 1946..2168
cPPT 1808..1823
RRE 1075..1308
HIV1 Psi packaging element 521..565
HIV1 5'LTR 230..410
LacZ alpha 7589..7657
M13-fwd 7518..7501
T7 7492..7472
HIV1 5'LTR 6904..7084
U3 PPT 6834..6855
cPPT 6834..6849
WPRE 6178..6753
RFP 5459..6169
IRES 4886..5458
F1 ori 7676..7982
LacO 10222..10244
M13-rev 10250..10270
T3 10288..10307
tetO-MIR human SOX10
10330 bp
ColE1 origin 9200..9882
AmpR 8443..9102
human SOX10 2271..4817
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TetO-MIR Hygromycin human SOX9 
 
 
VII.2. 2.2 Methods 
VII.2.1. Cell culture and cell lines  
The SCC cell line MET-4 was cultured at 37°C in 5% CO2 in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% Pen/Strep. This cell line was a 
kind gift from Prof. Petra Boukamp (DKFZ). HT-144 melanoma cells were cultured in DMEM 
with 10% FBS, 0.1mM β-mercapthoethanol, and 1% Pen/Strep. Transdifferentiated cells 
were cultured in MCDB 153 medium supplemented with 2% FBS, 20µg/ml bovine pituitary 
extract (bPE), 16nM 12-O-tetradecanoylphorbol 13-acetate (TPA), 1ng/ml basic fibroblast 
growth factor (bFGF), 5µg/ml insulin, 0.5µg/ml hydrocortisone, and 0.01mM forskolin.  
 
VII.2.2. Isolation and cultivation of primary human melanocytes 
Human melanocytes were isolated from foreskins, kindly provided by Dr. Uysal, Mannheim. 
Foreskin samples were incubated in 10% Braunol solution for 15min at room temperature. 
Subcutaneous fat was removed and the foreskins were cut into small pieces. During 
incubation at 4°C overnight in dispase (1 mg/ml) samples were digested. Digestion of the 
epidermis was performed with trypsin/EDTA for 15min at 37°C. Primary melanocytes were 
cultivated in medium 254 supplemented with 1% 100x human melanocyte growth 
supplement (HMGS) with a final concentration of 0.2% bovine pituitary extract, 0.5% FBS, 
1µg/ml recombinant human insulin-like growth factor-I, 5µg/ml bovine transferrin, 3ng/ml 
LoxP 2324..2357
minimal CMV promoter 2170..2229
TRE 1946..2168
central termination sequence 1906..1921
cPPT 1808..1823
RRE 1075..1308
HIV1 Psi packaging element 521..565
HIV1 5'LTR 230..410
M13-fwd 8083..8066
T7 8057..8037
HIV1 5'LTR 7469..7649
U3 PPT 7399..7420
cPPT 7399..7414
hygromycin B phosphotransferase 6345..7328
PGK promoter 5822..6326
PGK promoter 5817..6326
WPRE 5222..5797
LacZ alpha 8154..8222
Amp resistance promoter 8740..8768
AmpR 9008..9667
ColE1 origin 9765..10447
LacO 10787..10809
M13-rev 10815..10835
T3 10853..10872
tetO-MIR Hygromycin-human SOX9
10895 bp
F1 ori 8241..8547
RFP 4503..5213
human SOX9 2369..3898
mCherry 4503..5213
IRES 3998..4502
IRES 3930..3997
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basic fibroblast growth factor (bFGF), 0.18 µg/ml hydrocortisone, 3µg/ml heparin, and 
10ng/ml phorbol 12-myristate 13-acetate (PMA).  
 
VII.2.3. Bacteria transformation 
To amplify plasmid DNA DH5α competent Escheria coli (E.coli) bacteria were transformed. 
To this end, bacteria were thawed on ice and 10ng plasmid DNA was added. Bacteria and 
DNA was mixed gently before incubation on ice for 30min followed by heat shock at 42°C for 
3min. After 2min on ice 500µl LB medium was added. Then the bacteria were shaken at 
37°C for 30min. The transformed bacteria were spread on a selective agar plate and 
incubated overnight at 37°C for colony formation. Colonies were picked incubated in 5ml LB 
medium containing 100µg/ml ampicillin at 37°C overnight. The amplified plasmid DNA was 
isolated from this solution. Digestion with restriction enzymes was performed to confirm the 
presence of the specific plasmid. Bacteria containing the plasmid were incubated overnight 
on a shaker at 37°C in 200ml LB medium which contained 100µg/ml ampicillin. Subsequently 
the protocol of the Qiagen Plasmid purification Maxi Kit was followed to purify the plasmid 
DNA. After precipitation with isopropanol and ethanol plasmid DNA pellets were air dried and 
resolved in TE buffer. The NanoDrop ND-1000 was used to measure the concentration and 
for quality control.  
 
VII.2.4. Lentiviral vector production and antibiotic selection 
To produce lentiviral vectors, 770µl DMEM was mixed with 50µl Xtreme Gene9 and 
incubated at room temperature for 5min. Following the expression vectors encoding for the 
packing proteins gag, pol and rev and the envelop plasmid VSV-G in addition to the plasmid 
carrying the gene of interest were added. After an incubation of 30 min, the mixture was 
added to the HEK293T producer cells. After 12h, medium was changed. Medium was 
collected after 24h, 36h and 48h. The collected medium was filtered through a 0.45µm PVDF 
filter. Following, the supernatant was centrifuged for 5h 21,000rcf at 4°C in a high speed 
centrifuge and the virus was resuspended in PBS to store at -80°C. The concentrated virus 
was used to infect the cells. For the transdifferentiation assay, 4µl of centrifuged virus was 
added to the cells. The cells were washed with PBS before induction with doxycycline 
(1µg/ml). Cells were selected for M2 transactivator with 50µg/ml Zeocin and for the MITF 
reporter with 0.2µg/ml Puryomycin. 
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VII.2.5. RNA isolation, cDNA synthesis and quantitative RT-PCR analysis 
RNA was isolated from the cells using the RNeasy Kit supplied by Qiagen following the 
manufacture’s protocol. Briefly, cell pellets were lysed and RNA extracted using a column-
based purification. DNA digestion was performed during DNase I treatment for 15min at 
room temperature on the purification column followed by two washing steps and the elution 
in RNase-free water. The RNA concentration and quality was measured at 260nm using a 
NanoDrop ND-1000 Spectrophotometer. The RevertAid First Strand cDNA Synthesis Kit was 
used for cDNA synthesis according to the manufacturer’s advice, 500ng RNA was 
transcribed during 1h at 42°C followed by 5min at 70°C. The cDNA was diluted 1:5 in 
nuclease-free water and 2.5µl was used for analysis with quantitative RT-PCR (q-PCR) using 
SYBR Green PCR Master Mix and an Applied Biosystems 7500 Real-Time PCR System. 
The primer concentration used was 10mM. During q-PCR analysis, the expression of several 
keratinocyte markers and melanocyte markers was investigated. 18s was used as reference 
gene. Gene quantification was calculated using the Pfaffl method [170] calculating the delta-
delta Ct. Statistical analysis was carried out in Excel. 
Table 10: Q-PCR primers 
 Forward primer Reverse primer 
MITF endo ACCGTCTCTCACTGGATTGG CGTTGGGCTTGCTGTATGTG 
MITF total TGCCTGTCTCGGGAAACTTG CCAGTGCTCTTGCTTCAGAC 
SOX9 endo AGACCTTTGGGCTGCCTTAT TAGCCTCCCTCACTCCAAGA 
SOX9 total CTGAGCAGCGACGTCATCTC GTTGGGCGGCAGGTACTG 
SOX10 endo GGCTTTCTGTCTGGCTCACT TAGAGGGTCATTCCTGGGGG 
SOX10 total AGCCCAGGTGAAGACAGAGA ATAGGGTCCTGAGGGCTGAT 
LEF1 endo GCATCAGGTACAGGTCCAAGA TCTCCAGAAGAGGTCCTGGG 
LEF1 total AGAGCGAATGTCGTTGCTGA TCTTGGACCTGTACCTGATGC 
MITF GCTCACAGCGTGTATTTTTCC GCTCACAGCGTGTATTTTTCC 
DCT GGTTCCTTTCTTCCCTCCAG GGTTCCTTTCTTCCCTCCAG 
TRP1 AGCAGTAGTTGGCGCTTTGT AGCAGTAGTTGGCGCTTTGT 
TYR TTGTACTGCCTGCTGTGGAG TTGTACTGCCTGCTGTGGAG 
PAX3 CTGGAACATTTGCCCAGACT CTGGAACATTTGCCCAGACT 
EDNRB3 GTCCCAATATCTTGATCGCCAG AAGGCACCAGCTTACACATCT 
PMEL TCTGGGCTGAGCATTGGG AGACAGTCACTTCCATGGTGTGTG 
c-KIT TCATGGTCGGATCACAAAGA AGGGGCTGCTTCCTAAAGAG 
FOXD3 TCTGCGAGTTCATCAGCAAC GGGTCCAGGGTCCAGTAGTT 
KRT10 GCTGACCTGGAGATGCAAAT GCTGACCTGGAGATGCAAAT 
KRT14 AGGAGGTCACATCTCTGGATGACTG AGGAGGTCACATCTCTGGATGACTG 
Integrin beta 4 CTGTACCCGTATTGCGACT CTGTACCCGTATTGCGACT 
Integrin alpha 6 GCTGGTTATAATCCTTCAATATCAATTGT GCTGGTTATAATCCTTCAATATCAATTGT 
Loricrin GGAGTTGGAGGTGTTTTCCA GGAGTTGGAGGTGTTTTCCA 
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Involucrin CTCCATGTGTCATGGGATATG CTCCATGTGTCATGGGATATG 
IL-24 GACTTTAGCCAGCAGACCCTT GGTTGCAGTTGTGACACGAT 
SOX2 GCTAGTCTCCAAGCGACGAA GCAAGAAGCCTCTCCTTGAA 
18s GAGGATGAGGTGGAACGTGT GAGGATGAGGTGGAACGTGT 
 
VII.2.6. Protein extraction and western blot 
Cells were harvested in PBS and lysed in cell lysis buffer. Protein was harvested after 
centrifugation at 16,9000rcf for 15min at 4°C. The concentration was measured using the 
Pierce BCA Protein Assay kit. Under non-reducing conditions 40µg protein were separated 
by SDS-PAGE on 12% gels. Proteins were transferred onto polyvinylidene difluoride (PVDF) 
membranes during wetblotting with 60V for 1h at RT. After blocking in 5% non-fat dried milk 
in TBST for 1h at room temperature, the membrane was incubated overnight at 4C° with the 
following primary antibodies diluted in 5% non-fat dried milk: MITF (abcam ab80651, mouse 
mAb 1:1000), DCT (protein tech, rabbit pAb 1:1000), IL-24 (abcam ab56811, mouse mAb 
2µg/ml), beta-actin (Cell Signaling 13E5, rabbit mAb, 1:1000). Membranes were washed 
three times in TBS-T and subsequently incubated with a goat anti-rabbit or goat anti-mouse 
horseradish peroxidase linked antibody diluted 1:10000 in 5% non-fat dried milk in TBS-T at 
room temperature for 1h. Proteins were visualized by enhanced chemoluminescence (ECL) 
reagent as peroxidase substrate. 
 
VII.2.7. Electron microscopy 
Cells were seeded on aklar slides. Chemical fixation, dehydration, embedding, and imaging 
of the probes were performed by the Electron microscopy core facility at the DKFZ.  
 
VII.2.8. Gene expression profiling by microarray analysis 
Biological RNA triplicates of MET-4 cells and MT-MET-4 cells were sent to microarray 
analysis using Illumina HumanHT-12v4 Expression BeadChip according to the 
manufacturer’s instructions, at the German Cancer Research Center (DKFZ) Genomics and 
Proteomics Core Facility. In the core facility quality control, reverse transcription with 
labeling, chip hybridization and calculation of mean averages was conducted for each probe. 
Raw microarray data was quantile normalized using Chipster. Probes with a fold change <2 
and samples without annotation were removed before analysis. Following an empirical Bayes 
two groups test was conducted using to Benjamini-Hochberg (BH) p value adjustment with a 
threshold of p<0,05. Hierarchical clustering was performed for the genes differentially 
expressed using Spearman correlation as a distance measure. Gene set test was performed 
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with Chipster using the Kyoto Encyclopedia of Genes and Genomes (KEGG) or Gene 
Ontology (GO) annotation gene lists with BH p value adjustment with a threshold of p<0,05. 
The average linkage method was used to construct dendrograms out of the hierarchical 
clustering. Pathway analysis was conducted with Ingenuity Pathway Analysis (IPA). 
 
VII.2.9. DNA isolation and Methylation array analysis 
The Qiagen DNeasy Blood & Tissue Kit was used to isolate genomic DNA from MET-4 and 
MT-MET-4 cells according to the manufacturer’s protocol. In short, genomic DNA was 
isolated from the mixture through column purification and eluted in buffer AE, after cell lyses 
and digestion with proteinase K for ten minutes at 56°C. DNA concentration measurement 
and quality control was performed using a NanoDrop ND-1000 spectrophotometer. DNA 
isolated from MET-4 cells and MT-MET-4 cells was send to genome-wide methylation 
analysis using Illumina Infinium HumanMethylation450 BeadChips according to the 
manufacturer’s instructions, at the German Cancer Research Center (DKFZ) Genomics and 
Proteomics Core Facility. Such an array contains 483,854 probes to investigate the 
methylation status of CpG sites located in CpG islands (CGIs), CGI shores, CGI shelves and 
open sea regions. Methylation of individual sites is calculated as beta-value ranging from 0% 
(not methylated) to 100% (fully methylated). Analysis of the methylation data and gene set 
enrichment analysis (GSEA) of the microarray data combined with the methylation array data 
was kindly performed by Olga Bogatyrova (Cancer Epigenomics, DKFZ) using RnBeads, an 
R package from the Max-Planck-Institute Informatik and  GSEA software from the Broad 
Institute of MIT and Harvard, respectively. Inter- and intra-sample normalization was 
performed by raw data normalization via BMIQ-normalization using RnBeads R-Package 
(http://rnbeads.mpi-inf.mpg.de/). After quality control, the SNP probes (dbSNP132, 
n=92,428), probes with a p-value below 0.01 for at least one sample and probes with missing 
information were excluded. Also probes with methylation measurements in non CpG regions 
(n=3,156) were removes from the data set. Only weak batch effects were noted. Differentially 
methylated regions were analyzed on site and region level according to the sample groups 
specified in the analysis. The limma method was used to calculate the p value on the site 
level. The hierarchical linear model from R limma package were employed and fitted using 
an empirical Bayes approach on derived M-values. Differently methylated probes (DMPs) 
and regions (DMRs) were computed for MET-4 as increased or decreased compared to MT-
MET-4 via the differently methylated module from RnBead R package, according to the 
package vignette (http://rnbeads.mpi-inf.mpg.de/data/RnBeads.pdf). Several metrics were 
used to compute the differential methylation on the site level. Based on the following three 
criteria each site was assigned a rank: 1) comparison of the differences in mean methylation 
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levels of the two groups 2) the quotient of mean methylation and 3) a statistical test (t-test or 
limma depending on the settings) estimating if the methylation values in the two groups arise 
from different distributions. A combined rank is computed as the maximum (i.e. worst) rank 
among the three ranks. Higher evidence for differential methylation is indicated by a small 
combined rank. Only sites and regions which have been tested significant were included in 
further analysis. GSEA was applied to test if the defined gene set of hyper- and 
hypomethylated genes in MET-4 vs. MT-MET-4 revealed statistically significant differences 
between the two biological groups and if they are in agreement with the whole genome 
expression. Analysis was done using GSEA v2.1.0 Release 
(http://www.broadinstitute.org/gsea/). 
 
VII.2.10. Cell authentication and array CGH 
Cell lines were authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, 
Germany) as described recently [171]. Additionally, cell authentication was performed at the 
DKFZ genome core facility via comparative genomic hybridization (CGH) array analysis with 
the HumanCytoSNP-12 (SNP-Array with genome wide coverage) following the 
manufacturer's instructions. Analysis of the data was performed with GenomeStudio. 
 
VII.2.11. Cell growth assay and BrdU cell proliferation ELISA 
Cell growth was assessed by seeding cells in 6-well plates and counting them over a period 
of 16 days at 48h or 72h intervals.  Additionally the proliferation of the cells was monitored by 
performing a BrdU assay following the manufacturer’s protocol. After partial denaturation of 
the DNA strands immunochemical detection of BrdU is used to investigate the actively 
proliferating cells. Cells were seeded into a 96 well plate. After 24h BrdU was added and 
incubated for 24h at 37°C. Cells were fixed and DNA was denatured in one step by adding 
the fixing solution which was incubated for 30 min at room temperature. After washing the 
anti-BrdU detection antibody was added and incubated for 1h at room temperature. The 
peroxidase goat anti-mouse IgG conjugate was added and incubated for 30 min at room 
temperature. The TMB peroxidase substrate was pipetted on the plate and incubated for 30 
minutes in the dark. After adding the stopping solution, the absorbance was measured 
immediately at 450/490nm using the TECAN infinite F200 pro microplate reader. 
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VII.2.12. Viability and drug sensitivity assay 
To assess the cell viability, the alamarBlue cell viability assay reagent was used. This assay 
gives an indication for growth of the cells by detecting the metabolic activity. An oxidation-
reduction agent is used for this purpose which fluoresces upon chemical reduction of the 
culture medium due to proliferation of the cells. Cells were seeded in 96 well plates in 
triplicates and incubated at 37°C. After 24h, 48h and 72h, alamarBlue reagent was added in 
a 1:10 dilution. For the drug sensitivity test cells were treated with 5mM or 10mM 3-MA (3-
Methyladenine) or with 1µM or 10µM AKT VIII inhibitor. Some cells were also treated with a 
combination of both compounds. Cell viability was assessed after 48h of incubation. Cisplatin 
responsiveness was tested by treatment with 20µg/ml cisplatin for 48h. The fluorescence 
was measured with a TECAN infinite F200 pro microplate reader at 590nm 2h and/or 4h after 
addition of the solution. Cell viability was calculated from the resulting change in fluorescent 
intensity normalized to measurement at time point 24h 2h for cell viability, to the DMSO 
treated control in the drug sensitivity assay and to the untreated cells for cisplatin 
responsiveness. 
 
VII.2.13. Apoptosis assay 
The activity of caspase-3 and -7 was investigated using Apo-ONE® Homogeneous Caspase-
3/7 Assay. These two effector caspases are activated upon apoptotic cell death and 
therefore can be used as indicators for apoptosis in mammalian cells. Briefly, cells were 
seeded in 96-well plates in triplicate. On the next day the caspase buffer substrate mixture 
was added. The buffer lysed and permeabilized the cells. The profluorescent substrate 
rhodamine110 becomes fluorescent upon sequential cleavage by caspas-3/-7. After 3h 
fluorescence signal was measured at 485nm excitation and 535nm emission using the 
TECAN infinite F200 pro microplate reader.  
 
VII.2.14. Migration assay 
To study the migration potential of the cells, ibidi culture inserts were used. The inserts were 
placed into 6-well plates and cells were seeded into the separated chambers to 90% 
confluency. After starvation overnight, the proliferation inhibitor mitomycin C (500µg/ml) was 
added (1:500 for MET-4 and 1:4000 for MT-MET-4), the inserts were removed and migration 
was observed after 5h, 10h and 24h for MET-4 cells and for MT-MET-4 cells. Quantitative 
data analysis was performed with the software TScratch. 
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VII.2.15. Invasion assay 
The invasiveness of cells was analyzed using the Cultrex 24-Well BME Cell Invasion Assay 
according to the manufacturer’s protocol. In short, transwell chambers were coated with 1x, 
0.5x, and 0.1x BME (basal membrane extract) at 37°C overnight. Uncoated wells were used 
as migration control. After starvation with serum-free medium overnight, 100.000 cells per 
well were seeded in starvation medium in the top chamber. In the bottom chamber medium 
with 10% FCS was added as chemoattractant. The plate was incubated for 24h at 37°C. 
Migrated and invaded cells were lysed with a dissociation buffer containing Calcein, a 
fluorescent dye used for quantification. The TECAN infinite F200 pro microplate reader was 
used to measure fluorescence at 485nm excitation and 520 nm emission. 
 
VII.2.16. IL-24 ELISA 
To measure the secretion of IL-24, an ELISA assay was performed. The same amount of 
cells was seeded in 150µl in 96-well plates. After 5 days the supernatant was harvested and 
investigated. To the precoated ELISA plate sample or standard was added and incubated for 
2h at 37°C. Without washing Biotin antibody was added. After 1h incubation at 37°C the plate 
was washed and incubated with HRP-avidin for 1h at 37°C. The substrate TMB was added. 
After 15min the reaction was stopped by the administration of the stop solution. The optical 
density was determined within 5min at 450nm with a correction at 570nm using the TECAN 
infinite F200 pro microplate reader. The concentration was calculated with the software 
Curve Expert 1.4. 
 
VII.2.17. In vivo tumorigenicity assay 
To investigate the tumorigenicity 1,5x106 cells were resuspended in 50% Matrigel and 
injected subcutaneously into the flank of NSG mice. This mouse was developed by JAX 
Professor Leonard D. Shultz and lacks mature T cells, B cells, and is deficient for several 
high-affinity receptors for cytokines (including IL2, IL4, IL7, IL9, IL15, and IL21) that block the 
development of NK cells and further impair innate immunity. Consequently, the NSG mouse 
engrafts human cells and tissues better than any other published mouse strain [172]. Per cell 
line four mice were injected. Tumor formation was observed over 30 weeks. Mice were 
sacrificed as soon as the tumor reached a size of 1cm in diameter or if the mouse showed 
behavioral abnormalities. Tumors were fixed in 4% Paraformaldehyde (PFA) overnight and 
embedded in paraffin. Samples were sliced, cleared with xylene and rehydrated before 
antigen retrieval. Staining was performed with Pan-Cytokeratin (1:300) and counterstained 
with haematoxylin. Additionally a haematoxylin & eosin staining was performed for 
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histological analysis. The Leica DM LS light microscope was used for analysis of the 
samples. Sayran Arif-Said embedded the fixed samples in paraffin and performed the 
cutting, deparaffinization and staining of the slices. 
 
VII.2.18. Statistical analysis 
The software GraphPad Prims version 5.00 was used for statistical analysis. Statistical 
significance using two-tailed paired and unpaired t-test, two-way ANOVA, Mann-Whitney U 
test or Fisher’s exact test was determined if p < 0.05 (*), <0.01 (**) and 0.005 (***). 
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VIII. Results 
 
VIII.1. Identification of transcription factors which promote 
transdifferentiation into the melanocytic lineage 
 
In normal development and differentiation the specific interaction of several factors is 
necessary to determine cell fate. Therefore, we hypothesized that not only a single factor but 
a factor combination is necessary for transdifferentiation of cells from the keratinocytic into 
the melanocytic lineage. We had a pool of candidate genes which included transcription 
factors being involved in NC development, melanocyte differentiation, and which are highly 
expressed in melanocytes or upregulated during differentiation of iPSC into melanocytes. 
The candidate genes were cloned into doxycycline-inducible lentiviral vectors that co-
expressed red fluorescent protein (RFP) in order to monitor transgene expression. A reporter 
construct which contained green fluorescent protein (GFP) under the control of the 
melanocyte-specific MITF promoter region was used to detect expression of endogenous 
MITF. This MITF reporter construct was selectable with puromycin (Figure 4A). Additionally, 
co-infection with a lentiviral construct expressing the reverse tetracycline-controlled 
transactivator (rtTA or M2) was necessary to induce transgene expression. Cells, which 
carried this vector, were selectable with zeocin. Before testing various transcription factor 
cocktails cells were transfected with the M2 rtTA and the MITF reporter construct followed by 
antibiotic selection with zeocin and puromycin. After two weeks of antibiotic treatment all 
cells in this culture contained these two constructs (Figure 4B). 
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Figure 4: Schematic representation of the lentiviral vector constructs and workflow                  
A) Schematic representation of the lentiviral vectors carrying the MITF reporter construct and the 
transgenes used for transdifferentiation. The MITF reporter construct was used to monitor endogenous 
MITF expression. To this end, the MITF promoter region was coupled to a GFP site. Cells containing 
this vector could be selected with puromycin. The vectors containing the transdifferentiation factor 
carried a RFP site to make transgene expression visible under the fluorescence microscope. (GFP: 
green fluorescent protein, PGK: phosphoglycerate kinase, PuroR: puromycin resistance, TRE/CMV: 
tetracycline responsive element/cytomegalovir, IRES:  internal ribosomal entry site, RFP: red 
fluorescent protein). B) Workflow. Squamous cell carcinoma cell line MET-4 was transfected with the 
M2 transactivator and the MITF reporter construct.  Cells were selected with zeocin for the M2 
transactivator and with puromycin for the MITF reporter construct. After two weeks of antibiotic 
selection, cells were transfected with the transdifferentiation factors.   
For the validation of the MITF reporter construct primary human melanocytes and MET-4 
cells were transfected with this vector and GFP expression was observed. Strong GFP 
expression was noted for melanocytes due to high MITF expression. No GFP signal was 
detected in MET-4 cells since they do not express MITF (Figure 5A).The expression of the 
single transgenes was demonstrated via q-PCR. Endogenous expression as well as total 
expression was analysed in cells transfected with single factors uninduced or after induction 
with doxycycline. No endogenous expression was present for MITF, SOX10 and LEF1. 
Induction of the transgene led to a strong increase in total expression for these three genes. 
MITF expression was increased approximately 17-fold, SOX10 expression was almost 125-
fold enhanced, and LEF1 mRNA level was 122-fold higher due to transgene expression. 
SOX9 was already highly expressed in MET-4 cells so that the induction of the transgene did 
not significantly increase the overall expression (Figure 5B-E).  
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Figure 5: MITF reporter construct and transgene validation. A) Melanocytes and MET-4 cells were 
transfected with the MITF reporter. A strong GFP signal, which indicates MITF expression, was visible 
in melanocytes. In MET-4 cells MITF is not expressed and no GFP signal was detected. B-E) To 
validate the transgene vectors, MET-4 cells were transfected with single factors and expression was 
induced by doxycycline. The endogenous (endo) and total expression is calculated relative to the 
expression of the uninduced counterpart. Error bars indicate the SD of three independent experiments. 
P values were calculated by two-tailed, unpaired sample t-test. Asterisks indicate t-test p-value <0.05 
(*** p value < 0.005).  
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Cells were transfected with different combinations of transcription factors and the expression 
was induced by doxycycline. Two to three days after induction transgene expression could 
be observed by detecting RFP signal. Endogenous MITF expression indicated by GFP was 
visible approximately one week after induction (Figure 6A). In total cells were treated with 
doxycycline for two weeks before withdrawal. The medium was changed from DMEM to 
melanocyte differentiation medium MCDB one week after induction. 
Transgene expression was observed for all combinations whereas the RFP signal intensity 
varied according to the amount of virus used (Figure 6B). Not all factor combinations could 
induce GFP expression representing no endogenous MITF in these cells. The combination of 
MITF, SOX9 and SOX10 induced only weak GFP expression. Addition of LEF1 seemed to 
increase MITF expression (Figure 6B). Thus, the combination MITF, LEF1, SOX9 and 
SOX10 (MLS9S10) resulted in the highest GFP expression. 
  
Figure 6: Transgene expression and reporter activation. A) The transdifferentiation cocktail 
activated a strong RFP signal in the cells. Also several of these cells were GFP positive. Neither a 
RFP nor a GFP signal was detected in uninduced cells. B) Other transcription factor combinations 
could induce MITF expression in MET-4 cells as well. Yet, the GFP signal seemed strongest with the 
final transdifferentiation cocktail MITF, LEF1, SOX9, SOX10 (MLS9S10). 
Besides induction of endogenous MITF expression, several transcription factor combinations 
provoke morphological changes. Cells lost their cobblestone-like morphology and resembled 
melanocytes. Spindle shaped cells were present in culture which in addition lost the tight 
contact to the neighbouring cells. The amount of transdifferentiated cells varied depending 
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on the transcription factor combination used. Ectopic overexpression of solely MITF and 
SOX10 yielded only few spindle shaped cells. Addition of LEF-1 and SOX9 increased the 
transdifferentiation efficiency markedly. With the factor combination MLS9S10 approximately 
80% of the cells changed their morphology (Figure 7A). However, the transdifferentiated cells 
were quickly overgrown by the cells that did not change their phenotype. Therefore, the 
isolation and separate enrichment of the transdifferentiated cells was necessary. MET-4 cells 
attach strongly to the bottom of cell culture flask. The transdifferentiated cells could be 
enriched by serial trypsinization since the melanocyte-like cells detached faster than the 
original MET-4 cells. Comparison of the morphology of melanocyte transdifferentiated MET-4 
cells (MT-MET-4) to melanocytes showed obvious similarities (Figure 7B). 
 
Figure 7: Morphological changes. A) The transcription factor combinations which were able to 
induce MITF expression additionally led to morphological changes in the cells. Cells adapted spindle 
shaped morphology and lost the tight cell contact to neighbouring cells. The combination of MITF and 
SOX10 could induce these changes already, however only in a low cell number. Highest amount of 
cells with changed morphology was present in the culture which was transfected with the MLS9S10 
factor combination. B) Morphology of MET-4 cells, transdifferentiated MT-MET-4 cells and 
melanocytes. MET-4 cells showed cobblestone-like morphology and grew in tight colonies. The 
transdifferentiated MT-MET-4 cells adapted an elongated spindle shaped phenotype and lost the tight 
interaction with other cells comparable to melanocytes. Melanocytes were spindle shaped cells which 
grew as independent cells with only lose contact to other cells.  
After withdrawal of doxycycline, transgene expression was undetectable whereas the 
morphological changes remained (Figure 8A). Thus, the phenotype seemed to be transgene-
independent and therefore stable. MITF was described to be able to induce melanocytic 
characteristics in murine fibroblasts [165]. Transfection of cells with the transgene MITF 
alone was performed to test the effect of MITF overexpression in MET-4 cells. After induction 
of MITF transgene with doxycycline, several cells showed transgene expression indicated by 
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red fluorescence. However, ectopic expression of MITF alone was not sufficient to induce 
neither GFP expression nor morphological changes in MET-4 cells (Figure 8B, upper row). 
Thus, although MITF is the key player in melanocyte development and differentiation other 
factors were necessary for transdifferentiation. Since several cytokines which favour 
melanocyte differentiation are present in the MCDB medium MET-4 cells were cultured in this 
medium to test if the medium alone could induce melanocytic characteristics. However, MET-
4 did not survive under these conditions (Figure 8B, lower row). 
 
Figure 8: Effect of MITF and doxycycline withdrawal. A) After transfection with transgenes and 
induction with doxycycline strong transgene expression could be detected indicated by red 
fluorescence. After doxycycline withdrawal transgene expression was undetectable after one week but 
the cells kept their altered morphology. B) MET-4 cells were infected with MITF alone, cultured in 
DMEM or MCDB with and without induction with doxycycline. MET-4 cells cultured in DMEM grew 
normally. After induction transgene expression was observed however neither endogenous MITF 
expression nor morphological changes were noted. MET-4 cells did not survive culture in MCDB  
medium.  
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VIII.2. MT-MET-4 cells acquired melanocytic cell 
characteristics 
After enrichment of the transdifferentiated cells by serial trypsinization marker expression 
was analysed via q-PCR. All keratinocyte markers tested including Keratin10 (KRT10) and 
Keratin14 (KRT14), Integrin beta4 and Integrin alpha6 as well as Loricrin and Involucrin, 
were significantly down regulated in the transdifferentiated MT-MET-4 cells compared to 
parental MET-4 cells (Figure 9A). The expression in MT-MET-4 cells was reduced by two 
thirds for KRT10, while all the other keratinocyte markers were even more drastically 
downregulated. The key player in melanocyte differentiation, MITF, and the melanogenic 
enzymes were expressed after transdifferentiation, but only MITF and DCT were significantly 
upregulated. The expression of MITF was about 300-fold increased and DCT was 25-fold 
higher expressed (Figure 9B). On protein level expression of MITF and DCT could be 
confirmed with western blot. Two close but rather weak bands were present for DCT in the 
control lane where the melanoma cell line HT-144 was loaded. The same bands were 
present in the lane where the MT-MET-4 protein lysate was loaded. Yet, these bands were 
clearly stronger. DCT was not detected in the MET-4 protein lysate. The western blot for 
MITF revealed no clear bands but rather a smear between approximately 40kDa to 80kDa, 
which could be separated into three broad bands. Different isoforms of MITF have been 
detected because the antibody used detects melanocyte specific and nonmelanocytic 
isoforms of MITF. In the control lane the strongest signal was visible around 55kDa (Figure 
9C). This is around the actual size of the melanocyte specific MITF-M which is supposed to 
be detected at 54kDa and the phosphorylated form (pMITF-M) at 60kDa [173]. MITF-M is the 
smallest isoform of MITF and therefore migrates faster in an SDS-PAGE compared to the 
bigger isoforms. At these sizes very weak bands are present for MET-4 and stronger bands 
for MT-MET-4. Thus, MITF is slightly expressed in MET-4 cells and the expression is 
increased in the transdifferentiated form. Above these bands at around 80kDa a third band is 
present in MET-4 and MT-MET-4 while only a weak signal is visible for HT-144. This band 
indicates another non-melanocyte specific isoform, eventually MITF-A, since it is reported to 
be widely expressed. The other isoforms MITF-C, MITF-D and MITF-H are not expressed in 
melanoma cells [174, 175]. Additionally, melanocyte-related markers (EDNRB3, PAX3, and 
PMEL) and the MITF antagonists FOXD3 and SOX2 were tested (Figure 9D). Only a slight 
increase in expression was noted for PAX3 and EDNRB3 while the expression of PMEL and 
FOXD3 did not change. Yet, SOX2 expression was significantly reduced in MT-MET-4.  
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Figure 9: Keratinocyte and melanocyte marker expression. A) All keratinocyte markers tested 
were significantly downregulated in the MT-MET-4 cells relative to the expression in MET-4 cells. B) 
The expression of some melanocyte markers was upregulated after transdifferentiation. MITF and 
DCT were significantly upregulated. C) Western Blot of melanocyte markers MITF and DCT. 
Expression could be confirmed on protein level D) Expression of melanocyte-related markers such as 
EDNRB3, PAX3, PMEL, and FOXD3 was not activated. SOX2 was significantly downregulated in MT-
MET-4 cells. Error bars indicate the SD of three independent experiments. P values were calculated 
by two-tailed, unpaired sample t-test.  Asterisks indicate t-test p-value < 0.05 (*** p value < 0.005). 
 
One very important and distinct characteristic of melanocytes is the synthesis of melanin, 
known as melanogenesis and the presence of melanosomes. A whole genome expression 
array was performed and the resulting data was screened for genes related to 
melanogenesis. Gene set test in Chipster using the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) and Gene Ontology (GO) terms identified differential regulation of several 
pathways correlated to melanocytes and melanogenesis. The KEGG gene set test revealed 
that genes correlated to the terms lysosome, tyrosine metabolism, melanoma and 
melanogenesis were significantly differentially expressed (Figure 10A). Genes related to the 
terms melanosome, establishment of melanosome localization, melanosome localization, 
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melanosome transport, melanocyte differentiation were identified via analysis using GO. 
Additionally, eleven terms related to pigment or pigmentation were detected to be 
differentially regulated (Figure 10B+C). 
Gene test enrichment with KEGG performed in Chipster revealed a positive correlation of 
deregulated genes of MT-MET-4 cells to melanogenesis by showing approximately 80% of 
the 24 dysregulated genes being upregulated (Figure 10D). This upregulation indicated the 
activation of melanin synthesis, a hallmark of melanocytes and melanocyte-like cells. 
Amongst these positively correlated genes various genes related to WNT signaling were 
present. To these differentially regulated genes belongs one isoform of the WNT-receptor 
FZD, and two isoforms of TCF, a transcription factor of the WNT signaling pathway. 
Additionally, the MC1R, a MAPK isoform, two CREB isoforms, and a KIT ligand showed 
positive correlation to melanogenesis. Negative correlation was shown for the genes EDN1, 
TCF7, CREB3L2, WNT5A and LEF1. 
Electron microscopy revealed the presence of a few melanosome-like structures in MT-MET-
4 cells. They could be assigned to stage I to stage III melanosomes (Figure 10E). Small 
round vesicles with blebs inside, resembling early endosomes, indicated stage I 
melanosomes. Stage II melanosomes showed fibrils inside the lumen, while in stage III 
melanin was accumulated inside the vesicle. However, the melanin was not assembled on 
the fibrils. Thus, these organelles did not seem to contain fibril structures comparable to 
those seen in eumelanosomes but rather resembled melanosomes containing pheomelanin. 
In comparison, melanosomes of stage I-IV were observed in melanocytes. These 
melanosomes were electron dense and contained the typical fibrils (Figure 10F). 
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Figure 10: Melanin synthesis in MT-MET-4 cells. A-C) KEGG and GO gene set test showed 
positive correlation of gene expression in several genes related to melanocyte characteristics such as 
melanogenesis and pigmentation. D) Several genes related to melanogenesis showed a positive 
correlation. E) Melanosomes in stage I-III were present in MT-MET-4 cells F) Electron microscopy 
pictures showing melanosome stage I to IV in melanocytes.  
 
VIII.3. Correlation of MT-MET-4 gene expression to 
melanoma  
Differentiation of cancer cells into another cell type is hypothesized to lead to impaired 
tumorigenicity [167]. To investigate whether the tumorigenic SCCs were transdifferentiated 
into normal melanocytes or rather into the malignant form, melanoma cells, the whole 
genome expression of MET-4 and MT-MET-4 was compared to normal human melanocytes 
and five melanoma cell lines (Figure 11A). Opposite gene expression patterns were detected 
for primary melanocytes and melanoma cell lines. MET-4 and MT-MET-4 clustered closely 
together showing that the general gene expression was still comparable. The majority of the 
genes in MET-4 and MT-MET-4 showed similar expression pattern to the melanoma cell 
lines. Thus, a closer correlation between MET-4, MT-MET-4 and melanoma cells was 
identified compared to melanocytes. Nevertheless, some genes in MET-4 and MT-MET-4 
cells revealed an analogical expression pattern to melanocytes. Hierarchical clustering of the 
whole genome expression data of these samples demonstrated that the gene expression 
pattern of MT-MET-4 was not altered in a significant manner compared to the parental MET-
4 cells. Moreover, a closer correlation between melanoma cell lines and MT-MET-4 cells was 
detected compared to melanocytes. Thus, according to the whole genome expression 
analysis MT-MET-4 cells resemble melanoma cells rather than melanocytes. 
Gene set test using KEGG identified overall positive correlation of MT-MET-4 gene 
expression to melanoma. In total, 12 genes were differentially regulated in MT-MET-4 cells 
compared to MET-4 cells which correlated with melanoma (Figure 11B). Out of these 12 
genes eight showed a positive correlation and only four genes were negatively correlated. 
The genes with positive correlation were HRAS, PTEN, MAP2K1, PIK3CD, BAD, PIK3CA, 
ARAF and IGF1R. Negative correlation was related to EGFR, MET, PIK3R1 and E2F2. 
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Figure 11: Whole genome expression data. A) Microarray analysis revealed that the expression 
profile of MT-MET-4 is still comparable to the expression profile of MET-4 if compared with normal 
human melanocytes (NHM) and melanoma cell lines. The expression profile of MT-MET-4 cells is 
more similar to the expression profile of melanoma cells than to normal melanocytes. B) KEGG gene 
set test demonstrated a correlation to melanoma. The gene expression of several genes related to 
melanoma showed positive correlation. 
 
VIII.4. Minor genomic alterations and changes in 
methylation after transdifferentiation 
Structural changes of the genome are a profound source of genetic variations which has 
major effects on the phenotype. To exclude the possibility that the observed phenotype is 
due to genetic changes a single nucleotide polymorphism (SNP) analysis using comparable 
genome hybridization array (aCGH) was performed to compare the copy number of all 
sequences of the genomes of MET-4 and MT-MET-4. Amplifications, deletions, copy number 
changes and copy number neutral loss of heterozygosity (LOH) can be detected via this 
method. Copy number variation (CNV), thus increase or decrease of chromosomal copies for 
a given region, was analysed with Genome Studio. Depending on the signal intensity a 
certain colour code was applied to each sequence. Orange showed hemizygous deletions, 
green stood for LOH while blue was applied to regions which were amplified and white 
depicted presence of two copies.  
The two metrics for analysing CNV, B Allele Frequency (BAF) and Log R Ratio (LRR) were 
used. BAF is a normalized representation of the calls for B Allele. A deviation of an average 
of 0.5 implied CNV. This metric cannot distinguish between LOH and amplification since it is 
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not a genotype call. For signal intensity the LRR is used. This metric normalizes the signal 
intensity for CNV analysis. For each region an expected R value (equalling the sum of 
normalized red and green signal intensity) exists which was calculated based on pre-existing 
data. The ratio of observed R intensity and expected R intensity is determined for each 
region. The Log R ratio is calculated as follows: Log R ration = log2 (Robs/Rexp). A deviation 
from an average of 0 showed higher or lower signal intensity than expected for 2 
chromosomal copies [176].  
Overall high amplification was noted for MET-4 and MT-MET4 cells. Such genomic 
alterations are typical for cancer cells. A closer look at the copy number of the single 
chromosomes showed that most of the regions of the genome were present in the same 
copy number however also minor differences in copy number were detected. Three 
chromosomes, namely 2, 3 and 10 are depicted representatively (Figure 12 A-C). The small 
arm of chromosome 2, 2p, was amplified in MT-MET-4 cells while it was present at normal 
copy number in MET-4, indicated by the colours blue and white, respectively. The q arm of 
chromosome 2 was amplified for both cell types. Only a small sequence was deleted in MET-
4 cells. The colour code also differed for parts of chromosome 3, yet by detailed analysis no 
significant difference in copy number was detected. The signal measure for MT-MET-4 must 
have exceeded the threshold slightly so that instead of hemizygous deletion LOH was 
assigned. Chromosome 10 represented various alterations in copy number whereas the 
changes observed were the same in MET-4 and MT-MET-4. Further the loci of various genes 
of interest have been investigated. For most of the genes, including MITF, KRT14, ITGA6 as 
well as P53 and HRAS, no difference in CNV was noted (Figure 12 D-I). If differences were 
observed they did not relate to the phenotype seen. For example the locus of DCT was 
amplified in MET-4 cells while normal copy number was present in MT-MET-4 cells. Thus, 
the increased expression of DCT in MT-MET-4 cells is not due to higher copy number.  
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Figure 12: Comparative genome hybridization array (aCGH).  A-C) Copy number variation of 
single chromosomes. Most parts of the genome did not show any copy number variation. Yet, for 
example the small arm of chromosome 2 is amplified in MT-MET-4 cells while two copy numbers are 
present in MET-4 cells. Closer analysis revealed that the copy number of some loci was very similar 
but due to the threshold applied by the analysis software a different color code was assigned as for 
example seen on chromosome 3. The plot for chromosome 10 depicts high genetic alterations. Yet, 
they were the same for MET-4 and MT-MET-4. D-I) Copy number at certain gene loci. The loci of 
genes of interest have been analysed in detail. Most sequences analysed coding for melanocytic 
(MITF and DCT) or keratinocytic (KRT14 and ITGA6) markers were present in the same copy number. 
The locus of DCT was amplified in MET-4 cells but was present as two chromosomal copies in MT-
MET-4. Additionally no variation in copy number was detected for loci of several tumor suppressors 
and oncogenes. HRAS and P53 are shown representatively. 
 
In addition to the CNV analysis, two SNP analyses were performed. The genotype of almost 
300,000 SNP loci received from aCGH was analysed. Further, the quality control during 
methylation array analysis included another SNP analysis to identify sample mixup according 
to the genetic background. A heat map of the SNP probes was created for identification of 
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eventual sample mixup. The samples with the same genetic background should cluster 
together. 
For the first SNP analysis the genotypes of 293,869 loci were compared. Only 1,978 loci 
were identified with different genotype. Thus SNP analysis detected variation in the genotype 
of only 1% of the loci (Figure 13A). The SNP analysis which was included in the quality 
control could not differentiate MET-4 from MT-MET-4 cells according to the genetic 
background. The three samples for MT-MET-4 clustered close together. Additionally two 
samples of MET-4 clustered in close proximity to these three MT-MET-4 samples. These five 
samples clustered closer together than one of the MET-4 samples to the other two MET-4 
samples. Thus, according to the clustering resulting from the SNP analysis MET-4 and MT-
MET-4 samples are genetically undistinguishable (Figure 13B). These data show that the cell 
types still have the same genetic background. In conclusion, only minor genetic changes 
have occurred during transdifferentiation which were very unlikely to explain the phenotype. 
Epigenetic changes including methylation and histone modifications are supposed to occure 
during the processes of reprogramming and transdifferentiation. Yet, investigation of the 
methylation status of MET-4 and MT-MET-4 did not demonstrate significant changes. The 
three MET-4 samples clustered closely together and the MT-MET-4 samples clustered 
closely together indicating similar methylation pattern within each of the three samples of 
these cells. The distance between these two cell types, however, was still very close. The 
dendrogram of quantile normalized clustered samples depicted only very low distance below 
0.06 according to Pearson correlation (Figure 13C). In dendrograms the Pearson correlation 
indicates the distance between different samples which is given in 1- Pearson correlation. 
The global DNA methylation was clearly increased in the transdifferentiated cells. The 
methylation of MT-MET-4 was higher in the open sea regions, the islands as well as for the 
north shelf and north shore and the south shelf and south shore regions (Figure 13D). Thus, 
the overall methylation in MT-MET-4 samples was higher independent of the region. 
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Figure 13: SNP analysis and methylation array analysis.  A) aCGH SNP analysis. The genotype of 
293,869 loci of MET-4 and MT-MET-4 was compared. Only 1% (1,978 loci) of the loci had a different 
genotype. B) Methylation array SNP analysis. High similarity was detected between MT-MET-4 cells 
and MET-4 cells confirming that these two cell types are genomically still very similar and appeared 
here to be indistinguishable from each other. C) Dendrogram of methylation array analysis. All three 
MET-4 samples clustered together and all three MT-MET-4 samples clustered together. The distance 
between the two cell types was very low with a value below 0.06. Pearson correlation in dendrograms 
depicts the distance (distance = 1 - Pearson correlation) D) Global DNA methylation. General higher 
methylation was found in MT-MET-4 cells compared to MET-4 at every region of the genome. 
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VIII.5. MT-MET-4 cells exhibit a reduced malignant 
phenotype 
Different functional analyses were performed in order to measure the presence of cancer 
hallmarks such as increased proliferation, metabolic activity, apoptosis, and cell motility. 
According to their behaviour in culture, the transdifferentiated MT-MET-4 cells seemed to 
proliferate slower compared to the parental MET-4 cells. A growth analysis was performed to 
investigate cell proliferation by counting cell number over a period of 16 days. Significant 
differences in cell growth were measured. The cell number of MET-4 cells increased in a 
linear way during the whole observation time starting with 50,000 cells and reaching up to 
1x106 cells. In contrast, MT-MET-4 cells showed strongly decreased proliferation. After day 9 
the cell amount reached 2x105 which then remained relatively constant with only slight 
increase until the end of observation (Figure 14A). In addition to the growth curve a BrdU 
assay was performed as another measurement for cell proliferation. The amount of 
incorporated BrdU can be determined by measuring the intensity of the coloured reaction 
product. Its intensity is proportional to the amount BrdU incorporated into the DNA.  Cells 
were incubated for 24h with BrdU before measurement. A significantly higher signal was 
detected for MET-4 cells, indicating a higher proliferation rate. The absorbance was 
approximately three fold higher compared to the signal determined for MT-MET-4 (Figure 
14B). 
The metabolic activity was investigated using an alamarBlue assay with measurements 
taken at 24h, 72h, and 7d after seeding. After 24h almost the same signal was measured for 
MET-4 and MT-MET-4 cells. Yet after 72h and 7d in culture significant differences were 
observed. The increase in signal intensity was more pronounced for MET-4. The relative 
fluorescence unit (RFU) increased with a factor of 2.28 for MET-4 after 72h while the signal 
for MT-MET-4 increased approximately 1.76fold. In the final measurement after 7d the signal 
intensity for MT-MET-4 was not even half as strong as determined for MET-4 cells (Figure 
14C). Thus, in addition to reduced proliferation, MT-MET-4 cells showed markedly reduced 
metabolic activity. 
Inactivation of apoptosis signaling, the controlled cell death, can result in tumor initiation, 
promotion and metastasis and therefore plays a central role in a malignant phenotype [177, 
178]. The activity of caspase-3 and -7 was investigated as a measurement for apoptosis. In 
mammalian cells, the two caspases play crucial roles in programmed cell death. After 3h 
after addition of the caspase substrate a significantly higher signal was measure for MT-
MET-4 cells (Figure 14D). Thus, more active caspase-3 and/or -7 molecules were present. 
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Figure 14: Functional assays: Proliferation, cell metabolism and apoptosis.  A) Cell growth 
analysis. MET-4 cells grew in a linear way during the time of observation while MT-MET-4 cells almost 
stopped growing after 9 days. Error bars indicate the SD of three independent experiments. P value 
was calculated by two-way ANOVA, *** p value < 0.005. B) BrdU cell proliferation assay was 
performed. C) Cell metabolism assay. The metabolic activity of the cells was assessed at three time 
points (24h, 72h and 7d) after seeding. Statistical significant differences were noted after culture of 
72h and 7d. D) Apoptosis assay. The activity of caspase-3/-7 was investigated as a measurement for 
apoptosis. Error bars indicate the SD of three independent experiments. P values were calculated with 
two-tailed, paired sample t-test, p-value <0.05, (**p-value <0.01, *** p value < 0.005). 
Following, the cell movement and cell motility was investigated using a migration and an 
invasion assay. To study the migration potential of the cells Ibidi chambers were used to 
guaranty the same migration distance (Figure 15A+B). Cells were observed for 24h while 
treated with the proliferation inhibitor mitomycin C. Titration of the proliferation inhibitor was 
necessary because MT-MET-4 cells were more sensitive to the inhibition. The final 
concentration of proliferation inhibitor used was 1µg/ml for MET-4 cells and   0,125µg/ml for 
MT-MET-4 cells. MET-4 cells closed 50% of the free area after 10h and almost complete 
closure was noted after 24h. For MT-MET-4 cells minor reduction of the free area was visible 
within 10h and after 24h still 80% free area was measured (Figure 15C). 
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The invasion chamber assay revealed that the cells did not possess high invasive capacity. 
The chambers were coated with 1x, 0.5x and 0.1x basal membrane extract (BME). After 24h 
using 1x BME and 0.5x BME almost no cells were able to invade through the matrix. 
Therefore, invasive capacity was compared after 24h using 0.1xBME. The signal intensity 
measured for MT-MET-4 was only about 50% of the signal measured for MET-4 indicating a 
strongly reduced invasive potential of MT-MET-4 cells (Figure 15D). 
 
Figure 15: Cell motility.  A+B) Migration assay. Culture inserts with a defined cell free gap were used 
to analyse the migration potential of the cells. After 24h MET-4 cells covered the free area almost 
completely.The migration potential of MT-MET-4 cells was significantly reduced. C) Quantification of 
the migration potential. MET-4 cells were able to close more than 90% of the free area within 24h 
while 80% of the area was still free when using MT-MET-4 cells D) Transwell invasion assay. After 
24h the number of invaded cells using 0.1xBME was analysed. The fluorescence signal indicating the 
amount of invaded cells was 50% lower for MT-MET-4 cells compared to MET-4 cells. Error bars 
indicate the SD of three independent experiments. P values were calculated by two-tailed, paired 
sample t-test. Asterisks indicate t-test p-value <0.05 (** p value <0.01, ***p value < 0.005). 
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VIII.6. MT-MET-4 cells are less sensitive to a MET-4 
specific drug cocktail 
MET-4 cells are known to have high autophagic activity which also leads to reduced drug 
sensitivity. To circumvent this drug resistance autophagy inhibition combined with AKT 
inhibition (AKTi) was used. AKT is known to be involved in the development of skin cancer 
and therapy resistance. Further, mTOR, the master regulator of autophagy is a substrate for 
AKT. Inhibition of these two mechanisms in MET-4 cells resulted in increased sensitivity to 
cisplatin treatment [179]. Combination of autophagy inhibition and AKT inhibition was 
performed with MET-4 cells and MT-MET-4 cells to ascertain if MT-MET-4 cells are still 
dependent on autophagy and AKT signaling. After 48h of treatment MET-4 showed strongly 
reduced metabolic activity (Figure 16A). AKT inhibitor used at 1µM reduced the metabolic 
activity only slightly to about 80% of the metabolic activity measured in the control sample. 
Single treatment with either autophagy inhibition at both concentrations used or AKT 
inhibition (10µM) had pronounced influence on the viability of the cells. The metabolic activity 
of MET-4 cells was reduced to 46% for 5mM 3-Methyladenin (3-MA) and to 24% when using 
10mM 3-MA. Under the same treatment MT-MET-4 cells showed significant higher metabolic 
activity of 66% and 52%, respectively. Treatment with 10µM AKT inhibitor reduced the 
metabolic activity of MT-MET-4 cells to 55% while for MET-4 cells 33% was measured. At 
lower concentrations combination of these two treatments increased this effect. For example, 
if MET-4 cells were treated with 5mM 3-MA in combination with either 1µM or 10µM AKT 
inhibitor the metabolic activity was reduced from 46% to 39% or 26%, respectively. The 
same observation was made for MT-MET-4 cells. The metabolic activity of 66% after 5mM 3-
MA treatment was decreased to 59% and 44%, respectively, if additionally treated with 1µM 
or 10µM AKT inhibitor. Also the combination of 1µM AKT inhibitor with 5mM or 10mM 3-MA 
significantly reduced the metabolic activity of the cells. After treatment with 1µM AKT inhibitor 
the viability was reduced to 81% for MET-4 and to 87% for MT-MET-4. Additional 5mM or 
10mM 3-MA reduced the metabolic activity to 39% and 23%, respectively for MET-4 while 
59% and 44% of the basic metabolic activity was still measured in the MT-MET-4. However, 
administration of one compound at higher concentrations already led to strong reduction of 
metabolic activity in MET-4. Addition of another compound only slightly increased this effect. 
Specifically single treatment with 10mM 3-MA reduced the metabolic activity to 23% which 
was almost the maximum measured. Addition of 10µM AKT inhibitor caused solely another 
5% of reduction to ~19% metabolic activity. MT-MET-4 cells were less sensitive to the 
treatments. Especially single treatments did not have such a pronounced effect. Yet, here the 
addition of another compound had a stronger effect. In general, MT-MET-4 cells were 
significantly less sensitive to the drug administration compared to MET-4. 
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Figure 16: Drug sensitivity assay. A) MET-4 cells and MT-MET-4 cells were treated either with AKTi 
(1µM or 10µM) or the autophagy inhibitor 3-MA (5mM or 10mM) or with a combination of both 
compounds. After 48h the viability of the cells was measured. B+C) Cisplatin treatment. Cells were 
treated with 20µg/ml cisplatin for 48h. Error bars indicate the SD of three independent experiments. P 
values were calculated by two-tailed, paired sample t-test. Asterisks indicate t-test p-value <0.05 (** p 
value <0.01). 
Additionally MET-4 and MT-Met-4 cells were treated with cisplatin. After treatment with 
20µg/ml cisplatin for 24h almost all MET-4 cells seemed to be dead while MT-MET-4 cells 
did not seem to be strongly affected by the treatment (Figure 16B). After 48h the cell viability 
was measured using alamarBlue. MET-4 cells showed reduced metabolic activity to 
approximately 70% compared to the untreated sample while for MT-MET-4 cells almost 90% 
activity was measured (Figure 16C). 
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VIII.7. Loss of tumorigenic potential after 
transdifferentiation 
The comparison of the whole genome expression data of MT-MET-4 cells to melanocytes 
and melanoma cells revealed higher similarity of the gene expression profile of the 
transdifferentiated cells to melanoma cells rather than to melanocytes. On the other hand, 
functional assays showed reduced proliferation, cell metabolism, migration, and invasion 
capacity of MT-MET-4 cells in comparison to the parental MET-4 cells, indicating that the 
transdifferentiated cells might have a reduced or even impaired tumorigenic potential.  To 
assess the tumorigenic potential of MT-MET-4 cells in vivo they were injected 
subcutaneously into the flanks of NSG mice. Injection of cells into immunodeficient mice is 
the gold standard to test tumorigenic potential of cells. After 16 weeks first tumor growth was 
observed for MET-4 cells. In total, tumors grew in four out of four mice within 18 weeks after 
injection with MET-4 cells. In sharp contrast, no tumor formation within 30 weeks was 
detected after injection of MT-MET-4 cells (Figure 17A). Tumors isolated from mice which 
had been injected with MET-4 cells were positive for PAN-CK indicating that these tumors 
were from keratinocytic origin (Figure 17B). 
 
 
Figure 17: Tumorigenic potential in vivo.  A) After subcutaneous injection of 1,5x106 cells into the 
flank of NSG mice tumor growth was observed over 30 weeks. For each cell type 4 mice were 
injected. Tumor formation was observed for all 4 mice injected with MET-4 cells while no tumor growth 
was detected for MT-MET-4 cells. P-value was calculated with the Fisher’s exact test. Asterisks 
indicate t-test p-value <0.05. B) Staining of MET-4 tumor. The tumor which grew after MET-4 injection 
was PAN-CK positive. 
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Although the MT-MET-4 cells showed higher similarity in the gene expression profile to 
melanoma cells than to melanocytes, these cells seemed to have lost their tumorigenic 
potential. To investigate the mechanism behind this finding whole genome expression data 
were analysed. IL-24 was the top hit of this analysis with an increased expression of more 
than 5-fold (Figure 18A). Additionally, a methylation array was performed and the differential 
methylation between MET-4 and MT-MET-4 was analysed. Here again IL-24 was one of the 
tops hits showing statistically significant differential methylation. Investigation of IL-24 
revealed drastically reduced methylation of the promoter regions and the gene body of IL-24 
in MT-MET-4 cells. While 76% of the promoter region and 96% of the gene body were 
methylated in MET-4 cells only 14% of the promoter regions and 32% of the gene body were 
still methylated in MT-MET-4 cells (Figure 18B). The GSEA of the methylation data combined 
with the whole genome expression data confirmed the finding that the methylation status of 
IL-24 in MT-MET-4 cells was correlated to the expression of this gene (Figure 18C). 
Increased expression of IL-24 could be confirmed with q-PCR. The expression level was 
approximately 20-fold increased in MT-MET-4 relative to the expression in MET-4 (Figure 
18D). Analysis of the CNV of the genomic locus of IL-24 demonstrated that no genetic 
alteration was present between MET-4 and MT-MET-4 cells. In both cell types the locus of 
IL-24 was amplified (Figure 18E). Since IL-24 is a cytokine it needs to be secreted to be 
functionally active [180]. Therefore an IL-24 ELISA was performed. The concentration of IL-
24 in the supernatant after 5 days in culture was significantly higher for MT-MET-4 cells 
compared to MET-4 (Figure 18F). Thus, IL-24 was secreted as a cytokine and might execute 
its function via a receptor-mediated mechanism. However, the anti-tumor effect of IL-24 is 
not only related to its functions as a cytokine. It is suggested that intracellular IL-24 promotes 
the antiproliferative effect seen in tumor cells [181]. Therefore, not only an ELISA with the 
supernatant but also a western blot with cell lysate was performed. With this method, 
increased intracellular IL-24 was detected in MT-MET-4 cells (Figure 18G).Ingenuity pathway 
analysis (IPA) suggested correlation of IL-24 with reduced tumor growth. Specifically, IPA 
suggested that this gene is involved in reduced proliferation and growth of melanoma (Figure 
18H).  
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Figure 18: Identification of IL-24.  A) IL-24 was the top hit in the whole genome expression array 
with an upregulation of more than 5 fold. B) Methylation array analysis showed reduced methylation of 
IL-24 promoter region and gene body in MT-MET-4 cells C) GSEA identified hyper- and 
hypomethylated genes comparing MET-4 and MT-MET-4 and correlated these findings to whole 
genome expression data. IL-24 was a top hit after GSEA. D) IL-24 upregulation was confirmed via q-
PCR. E) Amplification of the IL-24 locus in MET-4 and MT-MET-4 was detected via aCGH analysis F) 
IL-24 ELISA. Higher concentration of IL-24 was measured in the supernatant of MT-MET-4 cells 
compared to MET-4. G) IL-24 Western Blot. Increased intracellular IL-24 protein levels were present. 
H) Ingenuity pathway analysis bioprofiler for IL-24 and melanoma. 
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TPA (12-O-tetradecanoylphorbol 13-acetate), one component of the melanocyte 
transdifferentiation medium, is known to induce IL-24 expression [182].To exclude that the 
observed phenotype was caused by TPA MET-4 cells were treated with TPA and TPA was 
removed from the transdifferentiation medium to investigate the effect on IL-24 expression. 
MET-4 cells treated with TPA died within 10h after addition of the compound to their normal 
culture medium DMEM. Probably TPA was the determining factor why MET-4 cells could not 
be cultured in the transdifferentiation medium. In the transdifferentiation medium without 
TPA, MET-4 cells could be kept in culture for about a week. The cells did not immediately 
die, however, they also did not proliferate and thus could still not be cultured in this medium 
(Supplementary Figure 1). The morphology of MT-MET-4 cells did not change after 
withdrawal of TPA (Supplementary Figure 2A). Investigation of IL-24 expression in MT-MET-
4 cells cultured without TPA revealed solely a slight decrease in expression (Supplementary 
Figure 2B).  
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IX. Discussion 
 
IX.1. Melanocytic characteristics and the issues of 
transdifferentiation 
This study shows that cancer cells from the keratinocytic lineage can be transdifferentiated 
into melanocyte-like cells by ectopic overexpression of the four transcription factors, MITF, 
LEF1, SOX9 and SOX10. Many keratinocyte markers tested were significantly 
downregulated indicating loss of keratinocytic characteristics. However, quantitative 
expression analysis still revealed high levels of integrin beta 4 and moderate expression of 
p63 and KRT14 in the transdifferentiated MT-MET-4 cells indicating that cells had not fully 
lost their keratinocytic transcription profile. On the other hand, melanocyte markers like the 
key transcription factor in melanocyte development, MITF, and DCT, one of the melanogenic 
enzymes, were significantly upregulated upon induction of the ectopic transcription factors. 
Analysis of the expression levels of the other two melanogenic enzymes TYR and TYRP1 via 
q-PCR only revealed slight upregulation. Also no other melanocyte-related markers were 
found to be expressed in the MT-MET-4 cells using q-PCR. Yet, according to the gene set 
test, several genes related to melanin synthesis and pigmentation were differentially 
regulated and various genes related to melanogenesis were regulated with positive 
correlation. SOX2 was significantly downregulated which is in agreement with the literature 
stating that MITF and SOX2 expression are mutually exclusive and that these genes 
influence the expression of each other [59]. Additionally, few melanosome-like structures 
could be detected in the transdifferentiated cells. The phenotype was stable and was 
maintained after doxycycline withdrawal. Thus, the effect seemed to be independent of 
transgene expression. Taken together, these findings indicate that the cells adapted some 
melanocytic chrarteristics, however probably did not fully transdifferentiate into the 
melanogenic lineage. Whole genome expression array analysis clearly showed that the 
transcriptional profile of MT-MET-4 cells still resembled the one of MET-4 cells to a great 
extent. Remarkably, the transdifferentiated cells, although not fully converted to the 
melanocytic lineage, did not possess tumorigenic potential anymore. 
Another explanation for the low melanocyte marker expression in SCCs upon induction of 
ectopic expression of transdifferentiation factors might be the presence of a heterogeneous 
population. Only a minor fraction of the cells had changed their morphology and adapted a 
complete melanocyte-like phenotype. Therefore, selection of the transdifferentiated cells was 
necessary. Here, serial trypsinization was used to enrich the transdifferentiated cells. This 
was possible since the melanocyte-like cells detached faster from the cell culture flask than 
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the parental MET-4 cells. This is a typical procedure for isolation of melanocytes from mixed 
cultures which also contain fibroblasts and keratinocytes. Treatment of the cells with G418 is 
another possible method since melanocytes are less sensitive to this antibiotic [183] than 
other cell types. However, the MET-4 cells were resistant to the treatment with G418. Thus, 
this selection method could not be utilized to remove the cells which did not transdifferentiate 
in order to create a homogenous cell population of melanocyte-like cells. In this study, a 
melanocyte-specific reporter construct was used to identify the cells which endogenously 
expressed MITF. GFP expression served as an indicator for the activation of this gene. It 
was attempted to sort GFP positive cells via fluorescence activated cell sorting (FACS), 
however the cells did not survive this treatment and therefore could not be taken into culture 
afterwards again. Above that GFP expression was diminished after a certain time in culture. 
It was not anymore possible to distinguish between the cells which had activated 
endogenous MITF expression and which had not. Selection according to melanocyte specific 
surface markers would have been an alternative option. Yet, no reliable surface marker was 
expressed in the transdifferentiated cells which could have been used. 
In order to promote transdifferentiation of SCCs, a defined medium was used that contained 
several growth factors which are known to promote melanocyte growth and differentiation. 
This medium contained, among others, basic fibroblast growth factor (bFGF), insulin, 
hydrocortisone, bovine pituitary extract (bPE), forskolin and 12-O-tetradecanoylphorbol 13-
acetate (TPA). The long-term proliferation of melanocytes is stimulated by bFGF [184]. 
Insulin, forskolin and bPE promote the growth of melanocytes [185, 186]. Additionally, bPE 
enhances the dendricity of these cells [187]. Hydrocortisone also stimulates the proliferation 
and differentiation of melanocytes [188]. TPA is known to enhance dendricity and 
proliferation of melanocytes and to lead to inhibition of apoptosis [189, 190]. Forskolin 
directly activates the adenylyl cyclase and increases the intracellular cAMP concentration 
[191] leading to activation of MITF transcription and induction of the melanogenic signaling 
network. Keratinocytes express bFGF to stimulate melanocyte proliferation and 
melanogenesis. Additionally, endothelin is expressed by keratinocytes which stimulates 
mitogenesis and melanin synthesis in melanocytes [192].  
Normal human melanocytes also need a cocktail of various cytokines and growth factors in 
the culture medium to be able to grow. It is known that melanocytes are dependent on the 
cytokine secretion of keratinocytes for proliferation and differentiation [193, 194]. Therefore, 
these cells cannot be passaged over a long period in culture especially without addition of 
sufficient growth stimulating factors. Also for the differentiation of ES or iPS cells 
differentiation media contained several additional factors to guide the cells into the 
melanocytic lineage [161, 164]. Interestingly, Nissan and colleagues succeeded in 
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differentiating iPS cells into melanocytes with only addition of BMP-4. However, after 
differentiation into melanocytes, the cells were seeded in medium containing human 
melanocyte growth factor supplements [164]. 
In the present study a strong effect of the medium on the phenotype of the SCCs was 
observed. The parental MET-4 cells could not be cultured in the melanocyte 
transdifferentiation medium. Only cells which underwent transdifferentiation were able to 
grow under these conditions. Yet, if transdifferentiated cells were cultivated in the medium 
used for the parental cells the phenotype quickly switched back and they lost the melanocytic 
morphology. TPA was identified to be the main factor causing death of MET-4 cells when 
cultivated in the transdifferentiation medium. TPA is a known tumor promoter which was 
used to eliminate fibroblasts and keratinocytes from mixed cultures with melanocytes [195]. 
Since MET-4 cells are from keratinocytic origin they might be sensitive to this factor. Above 
that TPA induced expression of IL-24. This cytokine is an antitumor gene which selectively 
kills tumor cells by apoptosis induction but does not harm ‘normal’ cells. This might also be 
an explanation why MET-4 cells died after addition of TPA. 
The genomic status can have enormous influence on the transdifferentiation ability of the 
cells. The p53 induced DNA damage response reduces the reprogramming efficiency. Often 
cancer cells carry p53 mutations which makes cells more amenable to transdifferentiation. 
This process is a stressful condition under which cells normally activate p53 and undergo 
apoptosis. If p53 is not present, the cells cannot activate this escape mechanism. In the 
literature it is stated that temporary suppression of p53 enhances the reprogramming 
efficiency [196]. Often, p53 is mutated in skin cancer cells from sun exposed sites. 
Additionally, the RAS genes, specifically HRAS, are commonly mutated in skin cancer cells. 
The genomic aberrations of MET-4 cells have been well characterized. These cells are wild 
type for p53 and all RAS genes [197]. Moreover, no genomic alterations were detected in the 
MT-MET-4 cells. This shows that no subclass of MET-4 cells with altered p53 or RAS loci 
was selected during transdifferentiation. Thus, this is not an explanation why MET-4 cells 
were at least partly responsive to transdifferentiation. 
Melanin synthesis is a distinct characteristic of melanocytes. To test if this process was 
activated in the transdifferentiated cells a gene set test was performed. Several terms 
correlated with pigmentation and melanosomes were differentially regulated. Additionally, 
several genes related to melanogenesis were differentially regulated leading to a positive 
correlation. Both findings indicated that melanin synthesis might have been induced. 
Presence of melanosomes can be demonstrated via electron microscopy. Melanosome-like 
structures were detected in the MT-MET-4 cells. However, only few of these vesicles were 
discovered. Beyond that, these structures did not resemble typical eumelanosomes which 
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have a fish bone-like structure and are elongated. The vesicles found in MT-MET-4 cells 
were spherical and did not show this intraluminal fibrillary organization. The electron dense 
parts, which were probably melanin, were condensed at certain areas inside the vesicle and 
not evenly distributed. This appearance resembles rather the one of pheomelanosomes, 
which contain the less abundant red or yellow melanin or immature eumelanosomes. Several 
factors are known to affect melanin synthesis and influence the type of melanin. Factors 
which have an effect on this process are for example tyrosinase activity, melanocortin 1 
receptor (MC1R) variants, as well as the concentration of cAMP and sulfur compounds [71]. 
Melanogenesis is a well-studied and in detail characterized process. The synthesis of 
melanin takes place in three distinct steps. First cysteinylDOPA (CD) isomers are formed 
until the cysteine concentration drops below 0.13 µM. Following pheomelanin is produced by 
oxidation of these CD isomers. This stage continues until the CD concentration falls below 9 
µM. Finally, the production of eumelanin is initiated. This only starts after most of the CD 
isomers and cysteine is exhausted. Thus, tyrosinase activity, tyrosine and cysteine 
availability determine the ratio of eumelanin to pheomelanin [198].  
Upregulation of tyrosinase expression was noted after transgene expression in MET-4 cells. 
However, after doxycycline withdrawal only low tyrosinase levels were measured in MT-MET-
4 cells on mRNA level. Low activity of the key enzyme in melanin synthesis is correlated with 
production of pheomelanin. Tyrosinase is responsible for the production of DOPAquinone. 
With low tyrosinase activity only few DOPA molecules are generated. The thiol compounds 
exceed the concentration of DOPA which leads to conjugation of DOPA with the thiol 
compounds. The DOPA molecules are then being trapped favoring pheomelanin synthesis 
[71].  
Binding of α-melanotropin to MC1R can stimulate the synthesis of eumelanin. However, the 
gene encoding this receptor is known to be highly polymorphic influencing the type of 
melanin. Distinct allelic variants are correlated to increased pheomelanin and skin cancer. 
Specific polymorphisms lead to loss of function and reduced response to melanotropin. Non-
functional MC1R has a significant influence on cAMP level and pigmentation since binding of 
α-melanotropin to the receptor normally stimulates cAMP production and tyrosinase activity 
in a dose-dependent manner. Specifically combinations of different alleles of MC1R are 
associated with this change in function. Melanocytes with these polymorphisms are more 
sensitive to UV radiation and resulting DNA damage. This probably explains the association 
of certain receptor variants to increased skin cancer risk [199].  
PMEL is responsible for the formation of the fibrillary structures inside the eumelanosomes 
[82]. Since this gene was not expressed in the MT-MET-4 cells, it might also be possible that 
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actually eumelanosomes are present in these cells, yet the structural protein is missing which 
gives rise to the typical shape and morphology. 
Successful transdifferentiation of one cell type into another depends on several factors, 
including transcription factor combination and method used to introduce these factors into the 
cells as well as cell type of origin and medium composition, which decisively determines the 
outcome and efficiency of this process. There is a multitude of explanations for low efficiency 
or incomplete transdifferentiation.  Firstly, in this work, multiple transcription factors were 
introduced into MET-4 cells with the help of lentiviral particles, which harboured one factor 
each.  Because of that, it was not guaranteed that all cells were infected with each factor or 
with the same ratio of factors. The result of a lentiviral vector infection is a heterogeneous 
population of cells that express different combinations of all the factors used at different 
levels. Wang and colleagues demonstrated that the stoichiometry of transdifferentiation 
factor expression levels correlates with the efficiency of transdifferentiation [200]. The 
concentration of transgene expression in the cell can also have crucial influence on the 
efficiency. Low expression might be sufficient to reduce the marker expression of the original 
cell line but cannot induce the transcriptional program of the cell type of interest. Additionally, 
transgene silencing can also affect the expression level and duration of transgene 
expression and thus reduce transdifferentiation efficiency. Since lentiviral vectors randomly 
integrate into the host genome, their integration might damage genomic sites which are 
essential for survival or proper functioning of the cell. Further cells can be refractory and do 
not manage to overcome transcriptional or epigenetic barriers to induce transdifferentiation 
[142, 167].  
Also the cell type of origin significantly determines the capacity and efficiency to 
transdifferentiate. The transdifferentiation of HaCaT cells, a cell line established from 
spontaneously immortalized keratinocytes from human skin, with MyoD1 to induce myogenic 
differentiation took longer than conversion of other cell types. Additionally, several 
keratinocyte differentiation markers were still expressed after transdifferentiation. After 
treatment with 5-aza-2'-deoxycytidine myogenic marker expression was increased but 
keratinocyte markers were unaffected [201]. 
Cells from the keratinocytic lineage seem to be more committed to their origin and more 
difficult to convert into other cell types. Wernig and colleagues noted very low 
transdifferentiation efficiency when transfecting keratinocytes with factors for induction of 
neuronal cell fate. They concluded that it is probably due to the chromatin state of 
keratinocytes at the binding sites of ASCL and BRN2 [202].   
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Above that the cell fate conversion of human cells in general is more complex than for 
murine cells. Cells from human origin seem to be more resistant to reprogramming towards 
pluripotency induced by ectopic expression of transcription factors [142]. Similar 
observations were reported for transdifferentiation of human cells [166]. Murine fibroblasts 
adapted melanocyte characteristics by only ectopically overexpressing MITF [165]. These 
cells adapted melanocyte morphology, expressed melanogenic markers and contained 
electron dense vesicles resembling immature melanosomes. In the MET-4 cells MITF alone 
did not have such an effect. MITF could be expressed ectopically in MET-4 cells; however, 
the activation of endogenous MITF transcription was not observed. Cells which only 
expressed MITF could also not survive in the melanocyte medium which should favour 
transdifferentiation. 
According to Yang and colleagues, the transdifferentiation of murine fibroblasts into 
melanocytes was faster than conversion of human fibroblasts. After 5 days of transcription 
factor induction in mouse embryonic fibroblasts (MEFs), melanocyte markers were 
expressed. The infected cells were cultured in the presence of G418 for 14 days to enrich 
melanocyte-like cells. Similar results were obtained with mouse tail fibroblasts. The efficiency 
of transdifferentiating human fibroblasts was much lower and it took longer to generate 
almost pure melanocyte populations. 40 days after infection of the human cells and selection 
with G418 only about 40% of the cells were positive for TYR and TYRP1. Human cells 
needed to be cultured for 100 days to gain 99.3% TYR positive cells [166]. 
Sometimes also additional factors are necessary to generate the same cell type from human 
cells compared to murine cells. For example, murine fibroblasts were converted into neurons 
by expression of only three factors, Ascl1, Brn2 (also called Pou3f2) and Myt1l [123]. The 
addition of NEUROD1 was necessary to generate neurons from human fibroblasts [203]. 
The factor combination identified in this study might not be sufficient to fully activate the 
endogenous transcription profile of melanocytic cells. Fibroblasts from murine and human 
origin were successfully transdifferentiated into functional melanocytes using the factors 
MITF, SOX10 and PAX3 [166]. Yang and colleagues used mouse fibroblasts which express 
GFP after endogenous activation of TYR. With this method first of all it was demonstrated 
that ectopic overexpression of SOX10 and MITF suffices to induce transdifferentiation 
towards the melanocytic lineage. Upon addition of a third factor highest amount of GFP 
positive cells with 10.06% was measured when PAX3 was added. The combination of 
SOX10, MITF and LEF1 yielded only 4.04% of GFP positive cells while SOX9 increased the 
percentage from 6.44% up to 9.53%. Thus, SOX9 also seemed to play an important role in 
the induction of the melanocytic transcription profile. The four factor combination SOX10, 
MITF, PAX3 and SOX9 only increased the amount of GFP positive cells from 10.06% to 
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10.71%.  The combination of MITF, SOX10 and PAX3 proved also effective in converting 
human fibroblasts to melanocytes. Considering the conclusions from this study, it might be 
that PAX3 was missing among the candidate factors used for transdifferentiating SCCs into 
fully functional melanocytes. PAX3 is described as a key player in melanocyte development 
[30, 58]. Important to consider is that at least 8 isoforms of PAX3 exist and different isoforms 
have distinct effects on melanocyte development [29, 33]. Yang and colleagues used PAX3e 
which seemed to be the relevant isoform. In contrast to this, the isoforms PAX3a, b, c, d, and 
i were among the candidate transcription factors used in our study. None of these PAX3 
isoforms favoured the transdifferentiation of SCCs into melanocytes. 
According to the observations made here SOX10 seemed to be essential for the 
transdifferentiation of SCCs into melanocytes. Only cells which had been infected with 
SOX10 showed high endogenous MITF expression. SOX10 might bind early to the DNA in 
this process thereby making the chromatin accessible for the other transcription factors, thus 
having ‘pioneer factor’ activity. Yet, binding of a single SOX10 protein to genomic loci does 
not alter transcription. Binding partners are necessary to elicit this function [204]. Possibly, 
SOX10 is essential to serve as a binding partner for the other transcription factors. During 
melanocyte development SOX10 and PAX3 form a complex to activate MITF. Thereupon, 
SOX10 and MITF cooperate to induce DCT and TYR expression [31, 45, 60]. 
Another SOX family member, SOX2, has been described as pioneer factor for certain genes 
in ESCs [205]. The role of SOX2 in melanocyte development is not completely clear. 
Adameyko and colleagues described a mutually exclusive expression of SOX2 and MITF. 
Further, SOX2 and MITF showed cross-regulatory effects in the development of melanocytes 
in the chick embryo. SOX2 repressed MITF expression and MITF supressed SOX2 
expression [59]. In contrast, Cimadamore and colleagues suggest that SOX2 is essential for 
endogenous expression of MITF in hESC-derived neural crest (hESC-NC) cells and normal 
human melanocytes in vitro [206]. In the present study, SOX2 was also downregulated upon 
transdifferentiation and upregulation of endogenous MITF expression supporting the cross-
regulatory effect of these two molecules.  
Mestre-Escorihuela proposed that due to accumulation of DNA methylation and 
chromosomal rearrangement, cell lines might eventually be more difficult to transdifferentiate 
[207]. It was demonstrated that higher methylation was present in primary cell lines 
compared to the tissue from which these cells haven been isolated from. Increase in 
methylation has been noted specifically in regions close to transcription start site [208]. 
Additionally, changes in DNA methylation of trophoblast cell lines were suggested to be 
induced during long term cultivation of these cells. The analysis of the methylation profile of 
cancer cell lines compared to primary tumors revealed that cancer cell lines in general 
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contain increased levels of CpG island hypermethylation than cells from primary tumors 
[209]. 
The chromatin state is a determining factor for accessibility of DNA binding sites for 
transcription factors. Open chromatin structures are necessary for most transcription factors 
to be able to bind and to initiate gene expression [210]. By analysing the chromatin state at 
certain loci which are known binding sites for the transcription factors used for 
transdifferentiation it is possible to estimate the responsiveness and efficiency of this 
process. Wernig and colleagues analysed the interaction of the three transcription factors 
ASCL1, BRN2 and MYT1L. Thereby, they identified a unique trivalent chromatin signature 
which was essential for ASCL1 binding [202]. Presence of this signature was predictive for 
the transdifferentiation of several cell types into neurons. For example, high enrichment of 
this trivalent chromatin state was present in human fibroblasts, while only low enrichment 
was noted in human keratinocytes. Resulting ASCL1 binding to the predicted sites was high 
in fibroblasts but very low in keratinocytes. Fibroblasts and other cells with enriched 
chromatin signature could be transdifferentiated into neurons. However, Wernig and 
colleagues were not successful to transdifferentiate keratinocytes into neurons with the same 
transcription factors. Additionally, they suggest a distinct hierarchy amongst these three 
factors. ASCL1 acted as a pioneer factor, binding first to the certain genomic sites and then 
recruiting BRN2 to these loci.  
Therefore, it would be of interest to analyse the chromatin state of the binding sites of SOX10 
and MITF to better understand the process of transdifferentiation into the melanocytic lineage 
and also study the interaction of these factors. Possibly, using this method, an additional cell 
line could be identified which can be transdifferentiated into melanocyte-like cells using the 
protocol established in this work. 
The differentiation state seems to play an important role in the amenability of cells to 
reprogramming and transdifferentiation [211]. The expression levels of lineage markers can 
be a hint for the differentiation status. Yet, the analysis of keratinocyte markers was not able 
to predict the transdifferentiation efficiency in SCC cell lines. Only in MET-4 cells, thus in one 
out of seven SCC cell lines, melanogenic characteristics could be induced by ectopic 
expression of the transcription factor combination. MET-4 cells, which are derived from a 
metastatic tumor [197], expressed low amounts of keratinocytic markers. The differentiation 
state of cancer cells often correlated with the progression of the disease. Tumor cells from 
metastasis are therefore often poorly differentiated [212]. However, some metastases 
especially from carcinomas are known to be well differentiated, sometimes even showing 
higher degree of differentiation compared to the primary tumor [213]. Since MET-4 cells are 
derived from a carcinoma it is difficult to draw a conclusion on the actual differentiation state 
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and if due to a low degree of differentiation these cells were more responsive to 
transdifferentiation. 
To increase the transdifferentiation efficiency OCT4 could be added to the cocktail. OCT4 
was identified to increase cell plasticity. It was shown, that OCT4 can lead to dedifferentiation 
of cells and global demethylation [214, 215]. The chromatin structures were opened, 
favouring reprogramming and transdifferentiation. Already the transient expression of OCT4 
is sufficient to make fibroblasts more amenable to transdifferentiation into early 
hematopoietic and neural progenitor cells using distinct media [214]. In addition, 
keratinocytes could be transdifferentiated into neuronal and contractile mesenchymal cell 
types by transient OCT4 expression [216].  
Epigenetic modulation can facilitate reprogramming and transdifferentiation events. 
Treatment of cells with demethylating agents such as 5-azacytidine enhanced the efficiency 
of cell fate conversion. For keratinocytes it has been shown that OCT4 expression led to 
global demethylation facilitating reprogramming of these cells [216, 217]. Following, 
Bickenbach and colleagues found out that decitabine treatment activated OCT4 transcription 
[218]. Later they discovered that single application of decitabine and culture in specific 
neuronal medium was sufficient to induce neuronal markers. Thus, epigenetic modifications 
have a pronounced influence on the cell plasticity and reprogramming efficiency.  [219].  
C-MYC is known to enhance the transcription of genes, which stimulate proliferation. 
Therefore, c-MYC was first thought to promote proliferation during somatic reprogramming 
[220]. However, the function of c-MYC as a transcription factor has been reconsidered. It was 
shown that c-MYC does not activate a certain set of target genes but rather amplifies the 
transcription at every active site in general [221, 222]. Considering these findings, expression 
of c-MYC should be able to favour any cell fate conversion event [220]. Thus, addition of c-
MYC to the transcription factor cocktail might stimulate the expression of melanogenic 
markers and promote transdifferentiation into the melanocytic lineage.  
IX.2. Genetics versus epigenetics in transdifferentiation 
and tumor formation 
Cancer cells are usually genomically unstable and continually accumulate genomic 
aberrations (reviewed in [223]). To exclude that the melanocytic phenotype and the impaired 
tumorigenic potential observed in the MT-MET-4 cells resulted from genomic alterations 
aCGH analysis was performed. This analysis revealed that few copy number variations 
(CNVs) were present. Yet, the majority of the genome showed exactly the same signal for 
corresponding sequences in MET-4 and MT-MET-4. Additionally, SNP analysis showed that 
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only 1% of the analysed loci varied in sequence. Thus, it is highly unlikely that the phenotype 
is caused by genomic alterations. 
Epigenetic alterations are known to take place during differentiation, reprogramming and are 
also suspected to happen during transformation of cells into tumor cells [128]. Promoter 
hypermethylation, which was found to be associated with CpG rich regions, is a prominent 
epigenetic alteration commonly found in several cancer cells. Especially the promoters of 
tumor suppressor genes were often strongly methylated leading to reduced or even 
suppressed expression [224]. This modification was identified to favour tumorigenesis. 
Therefore, suppression or removal of methylation was thought to be a possible cancer 
treatment. The demethylating agents 5-azacytidine (5-aza-C) or decitabin were used to treat 
cancer in the hope that this reactivates the expression of tumor suppressor genes which then 
counteract cellular transformation [225, 226]. In addition to promoter hypermethylation, global 
hypomethylation was discovered in cancer cells. It was identified as an early event in the 
transformation process while the extent of hypomethylation strongly depends on the type of 
cancer and the origin of the tumor sample [227-229]. Metastases seemed to be even more 
susceptible to global hypomethylation compared to cancer cells from the primary tumor [230]. 
Cells from cancer metastases are often less differentiated which might be related to the 
significant overall demethylation of the genome. The global hypomethylation increases 
genomic instability and can lead to activation of genes related to tumor promotion. 
Additionally, the interaction of euchromatin and heterochromatin is altered which also 
stimulates tumor formation [229]. Thus, the use of demethylating agents such as 5-aza-C 
might not always be beneficial but rather harmful. 
In this study, a methylation array was performed to investigate and compare the epigenetic 
landscapes of MET-4 and MT-MET-4 cells. The two different cell types could clearly be 
distinguished from each other, yet, overall only minor changes were observed. Since MET-4 
cells are of metastatic origin probably reduced methylation might be present in these cells in 
general. Global methylation analysis demonstrated increased methylation at every locus in 
MT-MET-4 cells indicating a more differentiated state. However, also the promoter regions 
were stronger methylated in MT-MET-4 cells. This analysis only shows the relative global 
methylation status in MT-MET-4 cells in comparison to the parental MET-4 cells. For this 
reason, it is not possible to distinguish whether the promoters in the MT-MET-4 cells were 
indeed hypermethylated or if the low methylation rate in MET-4 cells created the impression 
of a promoter hypermethylation in MT-MET-4 cells.  
Ballestar and colleagues compared the methylation status of pre B-cells and macrophages, 
which had been transdifferentiated from pre B cells. A high throughput methylation analysis 
of these two cell types detected no significant changes in the promoter regions of cell type-
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specific marker genes. Yet, histone marks had changed according to the altered gene 
transcription. Active histone modifications (H3K9/K14 acetylation and K4 trimethylation) were 
found at the promoter regions of macrophage-specific genes near the transcription start site 
in transdifferentiated cells and correlated with the activation of macrophage-associated 
genes. Additionally, H3K27 trimethylation (H3K27me3) was reduced at these sites. In 
accordance with this, the activating histone marks were decreased at B-cell-related genes 
while the suppressive marks did not increase in B cells during transdifferentiation. These 
findings suggest a hierarchy in epigenetic alterations. As a conclusion, histone regulators 
seemed to be more potent and could overcome repressive DNA methylation [231].  
In another transdifferentiation study the importance of histone marks was highlighted in 
addition. The modification of histones in a sequential manner seemed to be essential for 
stable transdifferentiation of hindgut cells into motor neurons in Caenorhabditis elgans (C. 
elegans). The demethylase JMJD-3.1, which specifically removes di- and trimethylation 
marks at lysine 27 of histone 3 (H3K27) and the methyltransferase Set1, which methylates 
histone 3 at lysine 4 (H3K4) were identified to play crucial roles in this process. Stepwise 
modifications of the histones by these two enzymes are necessary for a robust 
transdifferentiation event. It was suggested that Set1 and JMJD-3.1 play highly conserved 
roles to strengthen transcription factor induced changes in cell identity [136]. In our study, no 
significant differences in methylation at the loci of melanocyte and keratinocyte markers were 
noted. It would therefore be interesting to analyse the histone marks at these sites. 
According to the above mentioned studies it is likely that histone marks play a more 
important role in transdifferentiaiton and therefore rather influence genes expression and not 
methylation. 
These studies show important differences between transdifferentiation and reprogramming 
according to the epigenetic changes. While during transdifferentiation no major alterations in 
methylation were observed, the demethylation of promoter DNA is an important event for 
generation of pluripotent cells via reprogramming. Especially the promoters of NANOG and 
OCT4 need to be demethylated to establish a pluripotent state similar to ES cells [232]. Yet, 
besides these prominent demethylation events, total methylation landscapes vary 
significantly between ES and iPS cells. The epigenetic signature of somatic cell of origin was 
still present in the reprogrammed cells [233, 234]. Thus, a complete adaption of the 
methylation pattern is not necessary for significant changes in cell characteristics. These 
data confirm our findings. Significant changes in cell characteristics such as morphological 
changes and altered functional behaviour was observed while no major changes in 
methylation could be detected. According to these studies and our findings the methylation 
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landscape is not a reliable measure for cell fate conversion whereas histone marks should be 
taken into consideration instead. 
IX.3. Identification of IL-24 and its relation to the observed 
phenotype 
After microarray and methylation array analyses IL-24 was identified as a top hit. IL-24 
showed the strongest upregulation and its promoter as well as the gene body was highly 
demethylated. Upregulation of IL-24 after transdifferentiation into the melanogenic lineage 
might be a sign for adoption of the melanocytic phenotype and differentiation of the cells. In 
normal human melanocytes IL-24 is highly expressed. Its expression is still present in early 
stages of melanoma development but becomes downregulated during cancer progression 
and cannot be detected in advanced melanoma anymore [235, 236].The mda-7/IL-24 gene 
was discovered upon differentiation of melanoma cells which had been treated with 
interferon and mezerein [237]. This induced differentiation treatment leads to an increase in 
IL-24 expression. Therefore, IL-24 was first associated with terminal differentiation of 
melanoma cells.  
Several factors, which were present in the medium used for cultivating the transdifferentiating 
cells, stimulate melanocyte differentiation and might be involved in the upregulation of IL-24 
in MT-MET-4 cells. TPA for example is known to induce IL-24 expression and was found to 
increase promoter activity of IL-24 [182]. It was noted that TPA was involved in the 
upregulation of IL-24 in MT-MET-4 cells since there was a slight reduction of IL-24 
expression after TPA withdrawal. However, one can hypothesize that TPA is not alone 
responsible for the expression of IL-24. MT-MET-4 cells were not dependent on TPA since 
they also grew in medium without TPA and IL-24 was still expressed.  
To exclude that TPA alone was responsible for the induction of IL-24 MET-4 cells were 
treated with TPA and TPA was removed from the transdifferentiation medium. MET-4 cells 
died within 10h after addition of TPA to the medium. Removal of TPA resulted in slightly 
decreased expression of IL-24 but did not completely abolish its expression. Thus, it could be 
concluded that stimulated differentiation of MT-MET-4 cells resulted in IL-24 expression and 
TPA only increased its expression. However, it is not fully clear if transdifferentiation into 
another lineage alone was sufficient for the loss of tumorigenic potential. 
Various groups discovered that the treatment with IL-24 recombinant protein or ectopic 
expression of IL-24 with an adenovirus vector led to growth arrest and induction of apoptosis 
in cancer cells while IL-24 did not harm ‘normal’ cells [237]. Therefore, IL-24 was categorized 
as an anticancer gene which selectively induces cytotoxicity in cancer cells but not non-
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malignant cells. IL-24 does not belong to the tumor suppressor genes since its knock out did 
not lead to tumor formation [238]. 
IL-24 is involved in several mechanisms and can activate several signaling pathways which 
promote antitumor effects that are independent of the status of the tumor suppressors p53 
and RB [237]. Various apoptotic mediators, such as BAX, BAK, TRAIL, p53, and FAS, as 
well as several signaling molecules including PKR p38, PI3K, JNK and GSK-3 have been 
observed to be upregulated upon IL-24 expression [181, 239]. Depending on the cancer type 
different molecules are activated, however, it seems that all these molecules share a 
common cell death mechanism resulting in caspase activation and mitochondrial destruction. 
IL-24 especially induces cleavage of caspase-3 and caspase-9 [240]. Yet, the mechanism of 
action strongly depends on the cell or tissue type [181, 239]. For example, IL-24 induced 
apoptosis and growth arrest in G2/M phase in lung cancer cells with a parallel increase in 
p53, BAX and BAK [240].  
In melanoma however, expression of p38 and the resulting overexpression of GADD proteins 
was observed to be essential for activation of the cell death pathway [241]. 
The mechanism by which IL-24 exerts its effect depends on its cellular location. IL-24 can act 
intracellularly but is also secreted. If IL-24 is secreted it functions as a cytokine and binds to 
its receptors IL-20R1/IL-20R2 or IL-22R1/IL20R2. Receptor binding activates the JAK/STAT 
signaling pathway resulting in activation of STAT1 and STAT3 [242]. This activation can lead 
to apoptosis in cancer cells but also receptor-mediated STAT-independent apoptosis was 
reported [243]. In the immune system IL-24 receptor binding is suggested to activate the 
secretion of cytokines including TNF-α, IFN-γ and IL-6 [244, 245]. 
In addition to its induction of cytotoxicity IL-24 possesses an antimetastatic activity by 
reducing the migration potential and the invasive capacity of the cells. Significant inhibition of 
migration and invasion was reported after expression of IL-24 in vitro [246, 247]. The 
downregulation of matrix metalloproteinases (MMP-2 and -9), p85 PI3K and pFAK were 
responsible for this effect. No correlation with the cytotoxic effect of IL-24 was observed. 
Reduced number of lung metastases were noted when lung cancer cells had been treated 
with adenoviral IL-24 before intravenous injection into nude mice [248]. 
Since IL-24 has anticancer functions it might also be possible that due to its expression the 
cancer phenotype of MT-MET-4 cells was diminished. The effect of IL-24 on melanoma cells 
is very well described. Therefore, one likely explanation is that IL-24 had a significant 
influence on the tumor phenotype upon transdifferentiation. 
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The SCCs could have been transdifferentiated into the melanogenic lineage while retaining 
the tumor forming capacity. The tumorigenic phenotype is correlated with specific 
characteristics. Malignant tumor cells mostly show high proliferation, are highly invasive, and 
resistant to apoptosis. It was observed that melanoma cells are either highly proliferative but 
less invasive or the other way round [249]. Transformation into non-tumorigenic cells should 
negatively affect these characteristics. MT-MET-4 cells proliferated much slower, were less 
motile, and had significantly reduced invasive capacity. Additionally, apoptosis seemed to be 
upregulated indicated by increased caspase-3/-7 activity. The functional characterization of 
MT-MET-4 cells led to the conclusion that these cells do not resemble melanoma cells 
according to their behaviour. Thus, the functional assays performed comparing MET-4 and 
MT-MET-4 altogether provided indications that the transdifferentiated cells are less 
aggressive and might have reduced or lost tumorigenic potential.  
MET-4 cells are known to have high autophagic activity. They probably activated this process 
to increase survival. This is a typical mechanism of cancer cells to become more resistant to 
apoptosis and withstand stressful conditions [250]. Treatment of MET-4 cells with autophagy 
inhibitor and AKT inhibitor increased the sensitivity of these cells to cisplatin treatment. 
Cisplatin activates caspase-3 and stimulates apoptosis. By blocking autophagy the cells 
cannot use their typical escape mechanism and are more responsive to this treatment [179]. 
The transdifferentiated cells were less sensitive to the MET-4 specific treatment with the 
autophagy inhibitor 3-MA and AKT inhibition. This indicates that the MT-MET-4 cells might 
have undergone physiological changes, which render them less dependent on autophagy for 
survival.  
The study of Carette and co-workers supports the hypothesis that cell fate conversion can 
influence the responisveness to a specific treatment. Reprogramming of chronic myeloid 
leukemia cells which were dependent on the signaling of the fusion oncogene BCR-ABL 
(break-point cluster - abelson), made them lose this dependency thereby becoming resistant 
to the BCR-ABL inhibitor imatinib. They concluded that imatinib targets a specific population 
of chronic myeloid leukemia cells with a distinct epigenetic profile. Thus, the epigenetic 
differentiation state can influence the functionally of a compound or better the 
responsiveness of a cell to a certain treatment [251].  
Another explanation for the impaired tumorigenic potential might give the upregulation of IL-
24. It was shown that ectopic IL-24 expression in melanoma cells resulted in cytotoxicity. 
Inhibition of autophagy however reduced the cytotoxic effect of IL-24 on these cells. Thus, 
the reduced sensitivity of MT-MET-4 cells to autophagy inhibition might be due to reduced 
cytotoxic effect of IL-24. The original study additionally treated MET-4 cells with cisplatin. MT-
MET-4 cells might be more sensitive to this combination since Yacoub and colleagues could 
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show that IL-24 expression enhances the toxicity of cisplatin treatment [252]. IL-24 and 
cisplatin activate the procaspase-3 by cleavage and both activate JNK1/2 leading to cell 
toxicity. Additionally, cisplatin activates CD95, which was increased in the presence of IL-24. 
The toxic effect of radiation is also increase by IL-24 [253]. More autophagic vesicles were 
produced and increased ceramide and ROS signaling was noted. Again, inhibition of 
autophagy reduced this toxic effect induced by IL-24 and radiation. Yet, still a significant level 
of cell death was noted. Comparison of cisplatin treatment of MET-4 and MT-MET-4 
demonstrated reduced sensitivity of MT-MET-4 cells. This was probably due to the 
dramatically reduced proliferation of MT-MET-4 cells since chemotherapeutic drugs, such as 
cisplatin, target dividing cells [254, 255]. 
Injection of the cells into NSG mice confirmed the hypothesis that transdifferentiation of 
cancer cells induces a non-tumorigenic phenotype. While in all mice which had been injected 
with MET-4 cells tumor formation was observed no tumor growth was seen for MT-MET-4 
cells. Reduction of tumorigenicity by direct conversion was first shown by Graf and 
colleagues who converted B cell leukemia and lymphoma cell lines into macrophages. After 
transdifferentiation with ectopically overexpressing C/EBPα, the cells adapted macrophage 
characteristics and showed reduced tumor forming potential after injection into 
immunosuppressed mice [167]. 
IX.4. Transdifferentiation versus terminal differentiation 
Apart from transdifferentiation, terminal differentiation is a common approach to reduce or 
impair the tumorigenicity of cancer cells [168, 256]. It is believed that tumor cells activate 
mechanisms, which impair normal differentiation [257]. Forced upregulation of differentiation-
promoting factors could induce differentiation of cancer cells and lead to reduced growth and 
normalized signaling in these cells. One example for differentiation therapy is treatment of 
cancer cells with IL-24. This cytokine is used for differentiation of melanoma cells which 
leads to growth arrest in these cells [258]. 
Another hypothesis is that cancer cells block their natural differentiation program of their 
lineage of origin. Thus, for example brain tumor cells cannot be forced to differentiate into 
normal neurons. Yet, forced differentiation into another lineage should be possible. 
Additionally, reprogramming of cancer cells should release this block and make cells 
responsive to differentiation into cells of the same lineage but also of other lineages while 
impairing their tumorigenicity. Zhang and colleagues asked how far back a cell must be 
dedifferentiated to be able to differentiate into another lineage. With their study they showed 
that partial reprogramming of cancer cells is already sufficient to reverse the differentiation 
block and generate terminally differentiated cells from various lineages [168]. 
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Thus, it might be that due to transdifferentiation into another lineage the MET-4 cells gained 
their differentiation potential and adapted a more differentiated phenotype which resulted in 
lost tumorigenicity. 
In summary, this study shows that squamous cell carcinoma cells can be transdifferentiated 
into melanocyte-like cells using lentiviral vectors for ectopic overexpression of a defined set 
of transcription factors. Additionally, it is a proof of principle that via transdifferentiation the 
tumorigenic potential of cancer cells can be impaired. 
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X. Supplementary Figures 
 
 
Supplementary Figure 1: Effect of TPA on MET-4 cells. In medium containing TPA, Met-4 cells 
die within 24h. If MET-4 cells are seeded in MCDB medium without TPA cells do not 
immediately die. Yet, they lose their cell-cell attachment and seem to become senescent. 
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Supplementary Figure 2: Effect of TPA on MT-MET-4 cells and IL-24 expression. A) TPA does 
not have a strong effect on the morphology of MT-MET-4 cells. The culture medium 
influences the appearance of the cells strongly. B) TPA increases the expression of IL-24 in 
MT-MET-4 cells. MT-MET-4 cells express IL-24 also if they are culture in MCDB medium 
without TPA. MET-4 cells express only very low levels of IL-24.  
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XII. Abbreviations 
 
°C – Degree centigrade 
% - Percentage  
α –Alpha 
β- Beta 
µ - Micro 
3D – Three dimensional 
3-MA - 3-Methyladenine 
5-aza-C - 5-azacytidine 
7-AAD - 7-aminoactinomycin D 
 
aCGH - Comparative genome hybridization array 
AIM1- Absent in melanoma 1 
AKT - Protein kinase B 
AKTi – AKT inhibitor 
APS - Ammonium persulfate solution 
Arg151Cys -  Arginine to cystein change at position 151 
Arg160Trp - Arginine to tryptophan change at position 160 
ASCL1 - Achaete-scute homolog 1 
Asp294 - Aspartic acid at position 294 
Asp294His - Aspartate to histidine change at position 294 
BAF - B allel frequency  
BAK - Bcl-2 homologous antagonist/killer 
BAX - Bcl-2-associated X  
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BCA - Bicinchoninic acid 
BCC - Basal squamous cell carcinoma  
BCL2 - B-cell lymphoma 2 
bFGF - Basic fibroblast growth factor 
BH – Benjamini-Hochberg 
bHLH-LZ - Basic-helix–loop–helix-leucine-zipper  
BME - Basal membrane extract 
BMP - Bone morphogenic protein 
bPE - Bovine pituitary extract 
BrdU - Bromdesoxyuridin  
BRN2 - Murine brain-2 
BSA - Bovine serum albumin 
C. elegans - Caenorhabditis elegans 
CaCl2 - Calciumchlorid 
cAMP -  Cyclic adenosine monophosphate 
Caspase - Cysteinyl-aspartate specific protease 
CD19 - Cluster of differentiation 19 
cDNA - Complementary DNA 
CEBP - CCAAT-enhancer-binding protein 
c-KIT - Tyrosine kinase receptor 
cm - Centimeter 
CMV - Cytomegalovirus 
CNV - Copy number variation 
CpG - "—C—phosphate—G—", cytosine and guanine separated by only one phosphate 
CT - Cholera toxin 
Abbreviations 
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DCT - Dopachrome tautomerase 
DHI - 5,6-dihydroxyindole  
DHICA - 5,6-dihydroxyindol-2-carboxylat  
DLX2 - Distal-less homeobox 2 
DMEM - Dulbecco's modified eagle's medium 
DMSO - Dimethylsulfoxide 
DNA - Deoxyribonucleic acid 
dNTP - Deoxynucleotide 
dox - Doxycycline 
DSC - Dermal stem cells  
E - Embryonic day 
E. coli – Escheria coli 
EDN3 - Endothelin 3 
EM - Electron microscopy 
EMT - Epithelial to mesenchymal transition 
endo - endogenous 
ENDRB - Endothelin receptor type B 
ERK - Extracellular signal-regulated kinases 
ESC - Embryonic stem cell 
FACS - Fluorescence-activated cell sorting 
FCS - Fetal calf serum 
FOXD3 - Forkhead box D3 
FOXO – Forkhead box protein O 
G2/M - G2 phase/mitosis phase 
G418 - Geneticin 
Abbreviations 
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GATA4 - Globin transcription factor binding protein 4 
GFP - Green fluorescent protein 
GO - Gene Ontology 
GSK-3 - Glycogen synthase kinase-3 
h - Hour 
H3K27 - Histone 3 lysine 27 
H3K27me3 - H3K27 trimethylation 
H3K4 - Histone 3 lysine 4 
H3K9/K14 - Histone 3 lysine 9/lysine 14 
HaCat - Human adult low calcium high temperature keratinocytes 
HAND2 - Heart and neural crest derivatives expressed transcript 2 
hESC -  Human embryonic stem cell 
HMG - High mobility group  
HNF1α - HNF1 homeobox A 
H-RAS - Harvey rat sarcoma 
HRP - Horse radish peroxidase 
IFN-γ - Interferon gamma 
IL-20R1 - Interleukin-20 receptor 1 
IL-20R2 - Interleukin-20 receptor-2 
IL-22R1 - Interleukin-22 receptor 1 
IL-24 - Interleukin 24 
IL-6 - Interleukin 6 
IPA - Ingenuity pathway analysis 
iPSC - Induced pluripotent stem cell 
IRES - Internal ribosomal entry site 
Abbreviations 
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ITGA6 - Integrin alpha 6 
JAK – Janus kinase 
JMJD-3.1 - JuMonJi (transcription factor) domain protein 
JNK - c-Jun N-terminale kinase 
KRT10 - Keratin 10 
KRT14 - Keratin 14 
K4 - Lysine 4 
KEGG - Kyoto Encyclopedia of Genes and Genomes 
K-RAS - Kirsten rat sarcoma 
LB - Lysogeny broth 
LEF1 - Lymphoid enhancer-binding factor-1 
LOH - Loss of heterogeneity 
LRR - Log R ratio 
m - Milli 
mAb - Monoclonal antibody 
MAC1 - Macrophage-1 antigen 
MAFA - Maf musculoaponeurotic fibrosarcoma oncogene family, protein A 
MAPK - Mitogen-activated protein kinases 
MC1R - Melanocortin 1 receptor 
MCDB - Specific melanocyte medium 
mda-7 - Melanoma differentiation associated gene-7 
MEF2C - Myocyte enhancer factor 2C 
MITF - Microphthalmia-associated transcription factor 
MSA - Migration staging area  
MSH – Melanocyte-stimulating hormone 
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MT-MET-4 - Melanocyte transdifferentiated MET-4 
MYOD1 – Myogenic differentiation 1 
MYT1L - Myelin transcription factor 1-like 
NC - Neural crest 
NCC - Neural crest cells 
NGN - Neurogenin  
NGN2 - Neurogenin 2 
NHM - Normal human melanocytes 
N-RAS - Neuroblastoma rat sarcoma 
NT - Neural tube 
OCA1 - Oculocutaneous albinism type 1 
p - p-value (significance level) 
p38 - p38 MAP kinase 
P53 - Tumor protein p53 
PAX - Paired box  
PDX1 - Pancreatic and duodenal homeobox 1 
Pen/Strep – Penicillin/streptomycin 
PGK - Phosphoglycerate kinase 
PI3K - Phosphatidylinositol 3-kinase 
PKR - Protein kinase RNA-activated 
PMEL - Premelanosome protein 
PuroR - Puromycin resistance 
PVDF - Polyvinylidene difluoride 
RAS - Rat sarcoma 
RB - Retinoblastom 
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RFP - Red fluorescent protein 
RNA - Ribonucleic acid 
ROS - Reactive oxygen species 
rtTA - Reverse tetracycline-controlled transactivator 
S phase - Synthesis phase 
SCC - Squamous cell carcinoma 
SCF - Stem cell factor 
SDS-PAGE - Sodium dodecyl sulfate 
SNP - Single nucleotide polymorphism 
SOX10 - Sex determining region Y-box 10 
SOX9 - Sex retermining region Y-box 9 
STAT - Signal transducers and activators of transcription 
TBS - Tris-buffered saline 
TBX5 - T-Box 5 
TCF - T-cell factor 
TNF-α - Tumor necrosis factor alpha 
TPA - 12-tetradecanoylphorbol 13-acetate 
TRAIL - Tumor necrosis factor-related apoptosis-inducing ligand 
TRE - Tetracycline responsive element 
TYR - Tyrosinase 
TYRP1 - Tyrosinase-related protein 1 
US - United states of America 
UV - Ultra violet 
V - Volt 
WNT - Wingless/Intregrated 
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